Version :  4.3 January  5, 202 2  #S17 -[ZIP_CODE]  
i  
  
 
A PHASE  I/II RANDOMIZED,  DOUBLE -BLIND,  PLACEBO -CONTROLLED  TRIAL  OF CANNABIDIOL  
AS A TREATMENT  FOR  ALCOHOL  USE DISORDER  COMORBID  WITH  POSTTRAUMATIC  STRESS  
DISORDER  
 
Principal  Investigator:  [INVESTIGATOR_58577],  MD 
NYU School of Medicine, Department of  Psychiatry  
One Park  Ave 
[EMAIL_1103]  
[PHONE_1061]  
NYULMC Study  Number:  S17-[ZIP_CODE]  
Funding  Sponsor:  National Institute on Alcohol Abuse and Alcoholism  (NIAAA/NIH)  
IND/IDE Number:   140108  
Regulatory Sponsor:  Charles Marmar,  MD 
 NYU School of Medicine, Department of  Psychiatry  
One Park  Ave. 
[EMAIL_1103]  
[PHONE_1061]  
Michael Bogenschutz,  M.D.  
Professor of Psychiatry, NYU School of  Medicine  
Bellevue Hospi[INVESTIGATOR_58578]  
[ADDRESS_63800]  
A Building, 8th Floor, Rm.  A832  
[LOCATION_001], NY  [ZIP_CODE]  
Phone No: (646)  501-4026  
Email:  [EMAIL_1104]  
Study  Product:  Cannabidiol  
Study Product Provider:  Tilray  
ClinicalTrials.gov  Number  [STUDY_ID_REMOVED]  
 
 
Version :  4.3 January  5, 202 2  #S17 -[ZIP_CODE]  
ii  
  
 
 
Initial version:  July 19, 2018  
• Amended: July 25,  2018                                      
• Amended:  Nov 20, 2018  
• Amended:  Feb 21, 2019  
• Amended: June 17, 2019  
• Amended:  July 15, 2019  
• Amended:  August 21, 2019  
• Amended:  September 16, 2019  
• Amended: October 18, 2019  
• Amended : December 9, 2019  
• Amended : December 26, 2019  
• Amended : January 8, 2020  
• Amended : February 11, 2020  
• Amended:  March 2, 2020  
• Amended:  May 18, 2020  
• Amended : August 5, 2020  
• Amended:  August 28, 2020  
• Amended:  October 2, 2020  
• Amended:  December 3, 2020  
• Amended:  December 24, 2020  
• Amended:  April 14, 2021  
• Amended:  May 14, 2021  
• Amended:  June 2, 2021  
• Amended: June 23, 2021  
• Amended: October 6, 2021  
• Amended: October 26, 2021  
• Amended: December 1, 2021  
• Amended:  January 5, 202 2 
 
 
 
 
 Study number:  S17-[ZIP_CODE]  Page  3 
Version: 4. 3 
 
 
Statement of  Compliance  
 
This study will be conducted in accordance with the Code of Federal Regulations on the Protection of  Human  
Subjects  (45 CFR Part 46), 21 CFR Parts  50, 56, 312, and 812 as applicable,  any other  applicable  US 
government research regulations, and institutional research policies and procedures. The  International  
Conference on Harmonisation (“ICH”) Guideline for Good Clinical Practice (“GCP”) (sometimes referred to  as 
“ICH-GCP”  or “E6”)  will be applied  only to the extent  that it is compatible  with FDA and DHHS  regulations.  The 
Principal  Investigator  [INVESTIGATOR_58579],  or changes  to the protocol  will take place  without  prior 
agreement  from the sponsor  and documented  approval  from the Institutional  Review  Board  (IRB),  except  where  
necessary  to eliminate  an immediate  hazard(s)  to the trial participants.  All personnel  involved  in the conduct  of 
this study have completed Human Subjects Protection  Training.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as auth orized  in 
writing by [CONTACT_58636]:  03/20/2018  
 
 
 
Version :  4.3 #S17 -[ZIP_CODE]  
4  
 Contents   
1  Key Roles  ................................ ................................ ................................ ................................ .................... 10 
2  Introduction, Background Information and Scientific Rationale  ................................ .......................... 10 
2.1  Background Information and Relevant  Literature  ................................ ................................ ............... 10 
2.2  Name [CONTACT_58724]  ................................ ................................ ............ 11 
2.3  Rationale  ................................ ................................ ................................ ................................ ............. 13 
2.4  Potential Risks & Benefits  ................................ ................................ ................................ ................... 14 
3   Objectives and Purpose  ................................ ................................ ................................ ............................ 14 
3.1  Primary Objective  ................................ ................................ ................................ ................................ 14 
3.2  Secondary Objectives  ................................ ................................ ................................ ......................... 14 
4  Study Design and  Endpoints  ................................ ................................ ................................ .................... 15 
4.1  Description of Study Design ................................ ................................ ................................ ................ 15 
4.2  Study Endpoints  ................................ ................................ ................................ ................................ ..15 
5  Study Enrollment and Withdrawal  ................................ ................................ ................................ ........... 17 
5.1  Inclusion Criteria  ................................ ................................ ................................ ................................ .17 
5.2  Exclusion Criteria  ................................ ................................ ................................ ................................ 17 
5.3  Vulnerable populations  ................................ ................................ ................................ ....................... 18 
5.4  Strategies for Recruitment and Retention ................................ ................................ ........................... 18 
5.5  Duration of Study Participation  ................................ ................................ ................................ ........... 20 
5.6  Total Number of Participants and Sites  ................................ ................................ .............................. 20 
5.7  Participant Withdrawal or Termination  ................................ ................................ ................................ 20 
5.8  Premature Termination or Suspension of Study  ................................ ................................ ................. 21 
6  Study Agent (Study drug, device, biologic, vaccine etc.) and/or Procedural Intervention  ............... 21 
6.1 Study Agent(s) and Control  Description  ................................ ................................ ............................. [ADDRESS_63801] Storage and  Stability  ................................ ................................ ................................ ............. 22 
6.1.4  Preparation  ................................ ................................ ................................ ................................ .......... 22 
6.1.5  Dosing and Administration  ................................ ................................ ................................ .................. 22 
6.1.6  Route of Administration  ................................ ................................ ................................ ....................... 22 
6.1.7  Starting Dose and Dose Escalation Schedule  ................................ ................................ .................... 22 
6.1.8  Dose Adjustments/Modifications/Delays ................................ ................................ ............................. 22 
6.1.9  Duration of Therapy  ................................ ................................ ................................ ............................ 22 
6.2 Study Agent Accountability Procedures ................................ ................................ .............................. 22 
6.3 Study Behavioral or Social Intervention(s) ................................ ................................ .......................... 23 
7 Study Procedures and Schedule  ................................ ................................ ................................ ............. 24 
7.1 Study Procedures/Evaluations  ................................ ................................ ................................ ............ 24 
7.2 Laboratory  and Voice -markers  Procedures/Evaluations  ................................ ................................ ....26 
7.3 Study Schedule  ................................ ................................ ................................ ................................ ...27 
7.4 Concomitant Medications, Treatments, and Procedures ................................ ................................ ....34 
7.5 Prohibited Medications, Treatments, and Procedures ................................ ................................ ........ 34 
8 Definitions of Key Terms  ................................ ................................ ................................ .......................... 34 
9 Specification of Safety Variables  ................................ ................................ ................................ ............. 35 
10 General Guidelines  ................................ ................................ ................................ ................................ ....35 
10.1 Solicitation of AEs  ................................ ................................ ................................ ............................... 35 
10.2 Preplanned Hospi[INVESTIGATOR_58580] ................................ ................................ ........................... 35 
10.3 Reports of Cancer  ................................ ................................ ................................ ............................... 35 
10.4 Specific guidelines for assessing laboratory values as adverse events  ................................ ............. 35 
11 Assessment of Adverse Events  ................................ ................................ ................................ ............... 35 
11.1 Expectedness  ................................ ................................ ................................ ................................ ......36 
11.2 Severity  ................................ ................................ ................................ ................................ ............... 36 
11.3 Relatedness  ................................ ................................ ................................ ................................ ........ 36 
12 Monitoring Adverse Events  ................................ ................................ ................................ ...................... 36 
Version :  4.3 #S17 -[ADDRESS_63802] in the IP  ................................ ................................ ................................ .....40 
16.2 Temperature Deviations  ................................ ................................ ................................ ...................... 40 
17 Study Halting Rules  ................................ ................................ ................................ ................................ ...40 
18 Safety Oversight  ................................ ................................ ................................ ................................ ........ 40 
19 Clinical Monitoring  ................................ ................................ ................................ ................................ ....41 
20 Statistical Considerations ................................ ................................ ................................ ......................... 41 
21 Source Documents and Access to Sour ce Data/Documents  ................................ ............................... 45 
22 Quality Assurance and Quality Control ................................ ................................ ................................ ...45 
23 Ethics/Protection of Human  Subjects  ................................ ................................ ................................ .....[ADDRESS_63803]  ................................ ................................ ................................ .................. 46 
23.3 Informed Consent Process  ................................ ................................ ................................ ................. 46 
23.3.1  Consent/Assent and Other Informational Documents Provided to  Participants  ................................ .[ADDRESS_63804] Policy  ................................ ................................ ................................ ......................... 51 
27 References ................................ ................................ ................................ ................................ .................. 52 
 
Version :  4.3 #S17 -[ADDRESS_63805] of  Abbreviations  
 
AE Adverse  Event/Adverse  Experience  
CFR Code  of Federal  Regulations  
CRF Case  Report  Form  
CSOC  Clinical  Study  Oversight  Committee  
DCC  Data  Coordinating  Center  
DHHS  Department  of Health  and Human  Services  
DSMB  Data  and Safety  Monitoring  Board  
FFR Federal  Financial  Report  
FWA  Federal  Wide  Assurance  
GCP  Good  Clinical  Practice  
HIPAA  Health  Insurance  Portability  and Accountability  Act 
ICF Informed  Consent  Form  
ICH International  Conference  on Harmonization  
IRB Institutional  Review  Board  
ISM Independent  Safety  Monitor  
MOP  Manual of  Procedures  
n Number (typi[INVESTIGATOR_58581])  
NIH National  Institutes  of Health  
OHRP  Office  for Human  Research  Protections  
OHSR  Office  of Human  Subjects  Research  
PI [INVESTIGATOR_58582]/Serious  Adverse  Experience  
SOP  Standard  Operating  Procedure  
US United  States  
CBD  Cannabidiol  
THC Tetrahydrocannabinol  
AUD  Alcohol  Use Disorder  
PTSD  Post-Traumatic  Stress  Disorder  
Version :  4.3 #S17 -[ZIP_CODE]  
7  
  
 
Protocol  Summary  
 
 
Title A Phase I/II Randomized, Double -Blind, Placebo -Controlled Trial  of 
Cannabidiol  for Alcohol  Use Disorder  comorbid  with Post Traumatic  Stress  
Disorder  
 
 
 
 
 
Brief Summary  The proposed study is a double -blind, randomized proof -of-concept  study 
designed  to assess  feasibility  and contrast  effects  of CBD  treatment  to those  of 
placebo on safety, drinking -related outcomes and PTSD related outcomes  in 
patients  with AUD+ PTSD.  We will evaluate  the safety  of an extended  daily CBD 
treatment regimen in an AUD+PTSD population, measure resulting CBD,  THC, 
and anandamide levels, and generate preliminary data on the impact of  CBD on 
alcohol use, PTSD symptoms, and neuropsychological  and neurophysiological  
domain s implicated  in AUD  and PTSD.  150 participants  will be enro lled to 
randomize 48 eligible participants who fully meet study criteria in  a 5:3 ratio to 
receive either 600mg CBD/day  (PO) or placebo respectively for 6 weeks (N=30 
participants on CBD and N=18 participants on placebo).  Clinical interviews or 
portions of the interview will be audio taped to ensure quality control . De-
identified audio recordings of participants who consent to participate in the 
voice -markers analysis will be encrypted and sent via secure sites for analysis  
to a HIPAA compliant specialized labs.  
 
 Phase  Clinical study phase  I/II 
 
 
Objectives  To assess the safety and feasibility of administering CBD in an  AUD+PTSD  
population; to generate preliminary data on the effect of CBD in reducing  self- 
reported measures of alcohol use and PTSD symptoms and the impact of  CBD  
upon neurophysiological and neuropsychological domains relevant  to 
AUD+PTSD; to assess plasma for CBD, THC and anandamide  levels.  
Methodology  Double -blind,  placebo -controlled  
 
Endpoint  Primary endpoints: Adverse events and scores on psychomotor and  cognitive 
tasks,  number  of drinks  per day and PCL-5 total score.  Secondary  endpoints:  
circulating concentrations of CBD, THC and  anandamide.  
Study  Duration  2 years  
Participant  Duration  9 weeks  
Duration of  IP 
administration  6 weeks  
Population  n=48 (randomized) 18 –70 year -old males and females with moderate to 
severe AUD, as well as a DSM diagnosis of either PTSD or subthreshold 
PTSD in the [LOCATION_001] area.  
Study  Sites  [LOCATION_001] University Grossman School of  Medicine  
Number of  participants  150 participants expected to be  enrolled, 48 participants expected to be 
randomized  
Description of  Study  
Agent/Procedure  Cannabidiol PO  600mg/day  
Reference  Therapy  Placebo with medication  management  
Key Procedures  Blood  draws  
Version :  4.3 #S17 -[ZIP_CODE]  
8  
  
 
 
 
 
 
Statistica l Analysis  
The primar y outcom e measure  for AUD , the numbe r of drink s per day, is the change  
from baselin e to treatmen t end (week  6, T8), as analyze d with a Mixed Model  
Repeate d Measures  (MMRM)  with within and betwee n group comparisons.  The 
primar y outcom e measure  for PTSD , PCL-5 total score,  and secondary  outcome s 
for traumatic stress induce d craving  from the human laborator y task, and AUD and 
PTSD related  domain s will be analyze d in the same  manner.  
 
For secondary  outcome s plasma  levels within - and between -group comparisons  
of plasma  CBD levels will be assesse d at baseline (pre -CBD levels), followin g 
45 minutes (T1 - 45min post -CBD levels),  1 day (T2 - 45min post -CBD levels),  1 
week (T3 - 45min post -CBD and pre -CBD levels),  2 weeks (T4 - 45min post -CBD 
and pre -CBD levels), 4 week s (T6 - 45min post -CBD and pre -CBD lev els),6 week s 
(T8- 45min post -CBD and pre -CBD levels), and 7 weeks (T9 - pre-CBD levels) 
after the first CBD placeb o dose .  of dose will be assesse d and the 
interactio n between grou p and time-point s will be evaluated.  
Version :  4.3 #S17 -[ZIP_CODE]  
9  
  
 
Schematic of Study  Design  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Version :  4.3 #S17 -[ADDRESS_63806]. 8th Floor  
(646)  754-4855  
[EMAIL_1103]  
 
Esther Blessing, MD, PhD,  Co-Investigator  
NYU School of Medicine, Department of  Psychiatry  
One Park Ave. 8th Floor  
(646)  754-4808  
[EMAIL_1105]  
 
Michael Bogenschutz, M.D,  Co-Investigator.  
Bellevue Hospi[INVESTIGATOR_58578]  
[ADDRESS_63807]  
A Building, 8th Floor, Rm.  A832  
[LOCATION_001], NY  [ZIP_CODE]  
(646)  501-4026  
[EMAIL_1104]  
 
Gene Laska Ph.D,  Co-Investigator.  
[LOCATION_001] University Langone School of  Medicine 
One Park Avenue. 8th Floor  
[LOCATION_001], NY  [ZIP_CODE]  
(646)  754-4828  
[EMAIL_1106]  
 
John Rotrosen, MD,  Co-Investigator  
[LOCATION_001] University School of  Medicine 
Department of  Psychiatry  
One Park Ave, 8th  Fl 
(646)  754-4763  
[EMAIL_1107]  
 
2 Introduction, Background Information and Scientific  Rationale  
 
2.1 Background Information and Relevant  Literature  
 
Need for improved treatments for AUD comorbid with PTSD  
Alcohol use disorder (AUD) is one of the most common and debilitating psychiatric disorders. It has a  lifetime  
prevalence of ~29.1% in the [LOCATION_002], and is a major cause of medical and social disability,  preventable  
death and economic burden ($249 billion in 2010) [ 1, 2]. Several medications are available for treating  AUD,  
however associated effect sizes treatment compliance rates remain low [3] [4, 5]. A major barrier to  improving  
medical  treatment  of AUD  is the high level of heterogeneity  between  individuals  with this disorder:  AUD 
comprises  multiple  clinical  subtypes  with distinct  patterns  of alcohol  misuse  and distinct  psychological  and 
neurobiological disturbances. This means that a given medication may only work for certain subtypes of  AUD  
patients,  leading  to overall  lower  treatment  effectiveness  in the absence  of more  targeted  approaches.  Differing  
co-existi ng psychiatric  disorders  (present  in a high proportion  of individuals  with AUD)  make  an important  
contribution to this heterogeneity in [ 6-8]. The National institute of Alcohol use disorder (NIAAA) has  therefore  
emphasized ongoing drug development should address this heterogeneity by [CONTACT_58637],  particularly  those  that are common,  that 
involve severe AUD, and have low treatment response  [6-8]. 
Based on these criteria, the NIAAA recently mandated research to target medications to AUD comorbid  with 
post-traumatic  stress  disorder  (PTSD)  [6-8]. PTSD is a condition  that may develop  following  a traumatic  event:  
it involves intrusive thoughts about the traumatic event, avoidance of event relevant stimuli, negative  changes 
Version :  4.3 #S17 -[ZIP_CODE]  
11  
 in mood  and cognition,  heightened  vigilance  and physiological  arousal.  PTSD  is present  in 30–60% of 
individuals diagnosed with AUD and conversely 20 –70% of individuals diagnosed with PTSD meet criteria  for 
AUD,  with higher  rates  in military  veterans;  there  this comorbidity  (AUD+PTSD)  represents  a significant 
proportion  of all AUD  [9-14]. Subthreshold PTSD criteria requires that at least six symptoms of PTSD are present, but 
do not meet full threshold criteria due to failure to meet criterion specifiers. Previous research has shown that subthreshold 
PTSD is a clinically relevant concept. For instance, it has been found that psychiatric outpatients with subthreshold PTSD 
had social and occupation morbidity levels comparable to thos e with fully -threshold PTSD [104 ]. Other research has also 
found high rates of psychiatric comorbidity and psychosocial impairment in a sizable epi[INVESTIGATOR_39034] [105 ]. Similar 
outcomes have been s hown in samples of veterans [103 ]. When examining the leading subthreshold definitions utili zed 
by [CONTACT_58638] -symptom definition was found to trend toward significance and perform the best of all four definitions 
tested [102 ]. In addition,  AUD+PTSD/subthreshold PTSD  is associated  with more  severe  AUD,  higher  mortality  
and impairment and p oorer response to treatment. Findings also suggest that this comorbidity involves a vicious 
cycle  in which  each  disorder  exacerbates  and impedes  treatment  of the other  [10, 12, 15-22]; therefore,  
coordinated  treatment  of both disorders  should  be more  efficacious  than treating  each  disorder  in isolati on. 
Various medications have been tested for AUD or efficacy in randomized clinical trials involving  
AUD+PTSD/subthreshold PTSD  patients. However, no Phase III trials have been reported  [23]. 
 
Stress induced craving and extended amygdala activation as a target for treating AUD+PTSD  
Perhaps  the most  promising  medication  target  for treating  AUD+PTSD/subthreshold PTSD  is the addiction  
domain  of stress -induced  alcohol  craving,  with the neurobiol ogical  substrate  of increased  activity  in the 
extended  amygdala.  Clinical  studies  find that AUD+PTSD/subthreshold PTSD  patients  use alcohol  as a 
copi[INVESTIGATOR_58583]/subthreshold PTSD [10, 12, 15-22, 24-26]. Animal 
models show stress and alcohol craving are linked by  [CONTACT_58639],  namely  the extended  
amygdala,  and that pharmacological  inhibition  of stress  or ethanol -withdrawal associated activity in this area 
simultaneously reduces both anxiety and  ethanol -seeking  behaviors [ 27-29]. Receptor actions implicated in 
this inhibitory effect include cannabindoid 1  (CB1)  receptor stimulation and 5 -HT1a receptor activation [ 27-29]. 
Clinical and human experimental studies support the  idea that increased stress and amygdala activation 
increases alcohol craving and use. In AUD patients who  report alcohol use to mitigate negative emotions, 
higher amygdala reactivity predicts future problem drinking [ 30]. In PTSD/subthreshold PTSD pati ents, PTSD 
symptoms predict alcohol craving and use [ 16, 31]; further, a hyper -reactive  amygdala  response  to threat,  and 
heightened  sympathetic  physiological  arousal  including  skin conductance  and heart  rate, reliably  distinguishes  
PTSD/subthreshold PTSD  from controls  and predicts  PTSD  symptoms  [2, 32-34]. The well-validated  human 
laboratory paradigm of guided trauma imagery -elicited alcohol craving shows that trauma  re-experiencing  
elicits  negative  emotion,  physiological  arousal,  and alcohol  craving  [35-39]. 
 
Potential for CBD to treat AUD+PTSD /subthreshold PTSD  by [CONTACT_58640]  (CBD),  a pharmacologically  broad  spectrum  anxiolytic  and non-
psychotomimetic  phytocannabinoid  contained  in cannabis,  is a promising  drug candidate  for reducing  negative  
emotion -induced  alcohol  craving . In animal  models,  CBD  produces  anxiolytic,  anti-compulsive,  anti-fear-
conditioning  and pro-fear-extinction  effects,  by [CONTACT_58641]  1A (5-HT 1a) and CB 1 receptors  within  
extended  amygdala  areas  (the central  nucleus  [40], bed nucleus  of the stria terminalis  [41-43] and nucleus  
accumbens  shell [44]), and within functionally  connected brain regions including the periaqueductal grey [ 45], 
prelimbic and infralimbic regions of the  medial prefrontal  cortex  [46], and hippocampus  [47], reviewed  in [48]. 
CBD  indirectly  increases  endocannabinoid  agonism at the CB 1 receptor [ 49], an action that reduces extended 
amygdala output and alcohol seeking  [50]. CBD also potently reduced ethanol seeking in animal models of 
relapse during 7 -days of treatment, and  drug seeking remained fully attenuated up to 5 months following 
treatment termination [ 51]. In human  experimental  studies,  CBD  at doses  between  300–800 mg rapi[INVESTIGATOR_375]  (within  
2 hours)  reduces  subjective  anxiety  in both healthy  and social  anxiety  disorder  subjects,  and reduces  threat  
related  amygdala  activity  and sympathetic  arousal  measured by [CONTACT_58642] [ 52], reviewed in [ 48]. 
Importantly, skin conductance and amygdala  activation were  reduced  by [CONTACT_58643] a closely  correlated  manner  
[53], suggesting  threat  related  sympathetic  arousal  may serve  as a proxy  for amygdala  activation  [52]. These  
findings  suggest  that CBD  will reduce  extended  amygdala  activity  and negative  emotion  associated  with PTSD  
symptoms,  and thereby,  reduce  alcohol  craving and use. Further findings suggest that human laboratory 
measures of the subject and physiological effects  of traumatic  stress  upon  emotional  state  and alcohol  
craving  may serve  as a useful  measure  of drug target  engagement.  
 
a. Name [CONTACT_58725] :  4.3 #S17 -[ZIP_CODE]  
12  
 Cannabidiol  (CBD)  is a phytocannabinoid  constituent  of cannabis  that lacks  the psychotomimetic  and rewarding 
effects  of tetrahydrocannabinol  (THC)  [54], and has an excellent  safety  profile  in the human  experimental  
studies  and clinical  trials  reported  thus far [43, 55]. CBD  is a schedule  1 drug,  a class  that includes  compounds 
with high potential  for abuse  and no medical  value.  Contrary  to this scheduling,  CBD  does  not appear  to possess  
a high abuse potential. Nonetheless, this formulation has not been FDA -approved for medical use. Therefore, 
this study will  be performed  under  an Investigational  New Drug  Application  (140108 ). 
 
CBD has a broad spectrum of pharmacological effects. A s distinct from THC, CBD is a very  low-affinity  
cannabinoid  1 (CB 1) receptor  ligand;  nevertheless  CBD  appears  to achieve  an agonist  effect  at this receptor, 
potentially  by [CONTACT_58644]  (FAAH),  which  is the enzyme  responsible  for hydrolysis  
the endocannabinoid anandamide, which acts as CB [ADDRESS_63808] [ 49]. In addition to its impact on the 
endocannabinoid  system,  CBD  also acts as an agonist  at the serotonin  1A (5-HT1A) receptor  [42, 56]; 
produces  allosteric  modulation  of ligand -binding  kinetics  at μ and δ opi[INVESTIGATOR_58584]  [57]; increases  
intracellular  calcium  through  activation  of transient  receptor  potential  vanilloid  type 1 (TRPV1)  cation  
channels  [58]; enhances  adenosinergic  neurotransmission  via inhibition  of the adenosine  transporter  [59]; 
CBD also regulates, directly or indirectly, the peroxisome proliferator -activated receptor -γ, the orphan  G- 
protein -coupled receptor 55, the equilibrative nucleoside transporter, additio nal TRP channels,  glycine  
receptors  and GABA  recept ors [11, 12, 19, 21]. CBD  may also have  non-receptor  based  enzymatic  and other  
effects. Only some of these actions ( CB 1 and 5-HT1A actions) have been related to animal model effects  of CBD 
anxiolytic or anti -addictive effects  [48]. 
 
2.2.1  Preclinical Data  
As discussed, extensive evidence in animal models shows that CBD reduces anxiety behaviors,  compulsive 
behaviors, panic response and physiological stress responses by [CONTACT_58645]  [48]. This suggests the potential 
to reduce stress -induced craving. Several other effects of CBD may also act  improve  PTSD symptoms and 
combat alcohol addiction. Cannabidiol modifies consolidation and  reconsolidation, suggesting the ability to 
modify traumatic memories [ 48, 60]; CBD produces several pro -cognitive  effects:  including protecting against 
ethanol induced neurotoxicity [ 61], promoting hippocampal ne urogenesis  [47],  and attenuating  cognitive  
impairment  in several  animal  models  of neurodegenerative  disease  [62] [63]. 
 
Animal model studies also show that CBD reduces addictive behaviors: CBD reduces cue-induced  heroin  
seeking,  potentiates  extinction  of cocaine - and amphetamine -induced  conditioned  place  preference  [64], 
and normalizes heroin -seeking -induced changes in glutamatergic GluR1 -containing amino -hydroxy - methyl -
isoxazolepropi[INVESTIGATOR_58585] (AMPA) receptors and CB1 receptor expression in the nucleus accumbens  [65] induced 
by [CONTACT_58646] a delay discounting task 6 -15 days after the cessation of   treatment.  
 
2.2.2  Clinical Data to  Date  
Clinical  trials  in PTSD  or anxiety : No clinical  trials  of CBD  for PTSD /subthreshold PTSD  have  been  reported,  
nor for any anxiety  related outcome – although some trials in anxiety may be currently in progress. In human  
experimental  studies, CBD at doses between 300 –800 mg rapi[INVESTIGATOR_375] (within 2 hours) reduces subjective anxiety 
in both healthy and social anxiety disorder subjects, and CBD reduces threat -related amygdala activity  and 
sympathetic arousal measured by [CONTACT_58642] [ 66] [43, 48, 52]. 
 
Clinical  trials  in AUD:  No extended  clinical  trials  of CBD’s  effects  in alcohol  use disorder  or any addictive  
disorder have yet been reported. However, there are limited studies of CBD’s acute effects on  addiction - related  
behaviors.  The only study  to assess  the impact  of CBD on alcohol -related  behaviors  found  no impact of  200mg  
of CBD  on symptoms  of intoxication  in healthy  volunteers  [67]. CBD  was also reported  to reduce cigarette 
smoking in dependent humans [ 68], and a single case study reported that daily CBD  prevented  marijuana 
withdraw al symptoms  [69]. 
 
Other clinical data: A considerable and rapi[INVESTIGATOR_58586]’s  effects  in other  neuropsychiatric  disorders  (other  than PTSD /subthreshold PTSD  or AUD)  have  been  
conducted. Findings in general show CBD to have multiple therapeutic effects, including anxiolytic,  anti-
addictive,  anticonvulsive,  antipsychotic  and analgesic  [70], combined  with an excellent  safety  profile  and lack 
of adverse  effects [ 43, 55]. GW pharmaceuticals is developi[INVESTIGATOR_58587] (Epi[INVESTIGATOR_8321]®) as a medication for the 
treatment  of seizures associated with Lennox -Gastaut syndrome and Dravet s yndrome, and recently completed  
successful Phase 3 trials in 2016 [ 71, 72], and a successful Phase 2 trial in schizophrenia  [73]. 
 
2.2.3  Dose Rationale (If  applicable)  
Version :  4.3 #S17 -[ZIP_CODE]  
13  
 The proposed dose of 600 mg (~8 mg/kg) daily is within the range of doses (300 –800 mg) shown to  be anxiolytic  
in humans,  is expected  to be safe and tolerable  in humans  and to yield steady  state  levels  within  a safe and 
therapeutic  range.  
 
Anxiolytic  target  dose . As discussed  above,  human  experimental  studies  showed  that acute  oral CBD  in the 
300–[ADDRESS_63809]  doses  [48] although  no such  data yet support  this in humans.  
 
Safety : CBD was found to be safe and well tolerated in all Phase I and Phase IIa clinical trials  (>10) reported  
thus far, which  included  daily doses  up to [ADDRESS_63810] been reported safe in case studies, reviewed in [ 43, 74]. We considered dose titration, 
but elected not to because acute doses of up to 1500 mg, and repeated  daily doses of up to 1000 mg were 
previously safe and well tolerated [ 43, 74]. Regarding interactions  with alcohol,  a double -blind,  randomized  
placebo  controlled  acute  dosing  trial showed  that 200 mg PO CBD  did not increase  the psychomotor  effects  of 
alcohol  (1gm/kg)  or blood  alcohol  levels  [67]. Relevant  to the AUD  population, CBD showed no risk for abuse 
liability in humans  [75]. 
 
Potential  for dose  accumulation:  Regarding  repeated  dosing  pharmacokinetics,  two studies  in adults  that 
assessed plasma levels over repeated dosing showed no progressive accumulation of CBD  levels,  including  a 
6-week  trial of oral CBD  at 700 mg daily [67, 76]. Preliminary  data with transdermal  CBD  up to 30mg/kg/day in 
rodents shows no serum accumulation over 7 days of treatment (Weiss,  unpublished  data).  Therefore,  under  
the proposed  dosing  regimen  we expect  to achieve  steady -state  serum  levels  of CBD within a  week.  
 
2.3 Rationale  
There is an urgent need for medications that are effective in treating AUD+PTSD /subthreshold PTSD  
comorbidity, and which  are targeted to specific addiction domains and their neurobiological substrates. Pre -
clinical  and human  experimental  findings  suggest  the phytocannabinoid  CBD  is a promising  candidate  
medication  for reducing stress  induced  craving  by [CONTACT_58647],  in addition  to potential  
anti-addictive,  traumatic  and addictive memory modifying and pro -cognitive effects, thereby [CONTACT_58648] /subthreshold PTSD . This promise  is augmented  by [CONTACT_58649]’s  proven  
safety  record,  lack of intoxicating  effects  and low potential for abuse. Clinical trials of CBD in other disorders 
together with human experimental studies  provide  a strong  basis  for determining  a suitable  therapeutic  dose  
for AUD +PTSD /subthreshold PTSD . There  are few or no clinical  trials  reported of CBD for AUD, 
PTSD /subthreshold PTSD , or more generally for stress and addiction disorders, creating a mandate  for the 
current  trial. 
The proposed study is a double -blind, randomized proof -of-concept study designed to assess feasibility  and 
contrast effects of CBD treatment to those of placebo on safety, drinking -related outcomes and 
PTSD /subthreshold PTSD  related outcomes  in patients  with AUD+PTSD /subthreshold PTSD . We will evaluate  
the safety  of an extended  daily CBD  treatment  regimen in  an AUD+PTSD /subthreshold PTSD  population  and 
measure  resulting  CBD,  THC,  and anandamide  levels.  We will also generate  preliminary data on the impact of 
CBD on alcohol use, PTSD symptoms, a human laboratory traumatic  stress induced craving task, 
neuropsychological and neurophysiological domains implicated in AUD and PTSD /subthreshold PTSD , and 
cognitive ability. Cannabidiol levels will be obtained from CBD -treated participants to estimate the plasma levels 
corresponding with  putative therapeutic  effects  and to determine  whether  dose  accumulation  occurs.  THC 
levels  will be obtained from CBD -treated participants  to determine  whether  CBD  metabolites  are converted  
into THC,  as has been  suggested  in the literature  [77]. Anandamide levels will be obtained from all participants 
to test whether CBD elevates plasma anandamide, and to  provide  preliminary  data for relating  anandamide  
levels  to putative  therapeutic  effects.  Following  screeni ng and baseline  assessments,  48 participants  will be 
randomized  in a 5:3 ratio to receive  either  600mg CBD/day (PO) or placebo  respectively for 6 weeks (N=30 
participants on CBD and N=18 participants on placebo). Safety measures (adverse events, cognitive  and 
motoric  function),  drinking  related  outcomes  and PTSD  symptoms  will be assessed  weekly  throughout  the 
study.  Human  laboratory  tasks,  neuropsychological  domains  implicated  in AUD  and PTSD /subthreshold PTSD  
and cognition  will be assessed  at baseline  and at the end of treatment.  Measurement of circulating levels of 
Delta -[ADDRESS_63811] dose  of CBD  vs. placebo. Anandamide levels will be obtained from both CBD - and placebo -treated 
participants  at the aforementioned timepoints.  
 
Version :  4.3 #S17 -[ZIP_CODE]  
14  
 2.4 Potential Risks &  Benefits  
 
2.3.[ADDRESS_63812] revealed few adverse effects of CBD  orally  in doses  
ranging  from 10 mg to 1500  mg per day; there  have  been  no reported  effects  on blood  pressure,  heart rate, or 
respi[INVESTIGATOR_697], no negative mood effects, and no psychomotor slowing. Commonly  reported treatment -
emergent adverse events in Phase 3 trials of CBD for Lennox -Gastaut or Dravet  Syndrome  included  diarrhea, 
somnolence,  pyrexia,  decreased  appetite,  vomiting,  fatigue,  lethargy,  convulsion, and elevated liver enzymes.  
All participants  in these  trials  were  on concomitant  anti-seizure  medications.  CBD  is not noticeably  
psychoactive.  
 
2.3.2  Incidental Findings  
In some cases, the safety blood draw results may indicate an abnormality with (or without) a clinical 
significance. Every blood draw performed in this study will be saved and handled under the standard PHI 
confidentiality restrictions and regulations employed for patients’ information. The results are always reviewed 
by a licensed nurse practitioner or an MD, who may then detect an abnormality. If clinically useful information 
is uncovered, either the Principal Investigator [INVESTIGATOR_58588]. A copy of the original report will also be provided 
to the participant who will then be advised to consult with their treating physician.  
 
2.3.[ADDRESS_63813]  size 
of CBD  in reducing  self-reported  measures  of alcohol  use and PTSD  symptoms  in the AUD+PTSD/subthreshold 
PTSD  population.  
We predict  that treatment  with 600mg  CBD  daily will be well tolerated  with no greater  psychomotor  or other  
motor side effects compared to treatment with placebo. We predict that CBD will be associated with a  greater  
reduction in drinks per day and PTSD symptoms (total PCL -5 score) compared to  placebo.  
 
3.2 Secondary Objectives  
Secondary objectives of this study are as  follows.  
1) To assess the effect of CBD upon plasma CBD and THC levels when administered to patients  with 
AUD+PTSD /subthreshold PTSD . We predict  that within -group plasma  CBD  levels  will stabilize  within  one 
week,  i.e. [ADDRESS_63814] -CBD dosing  levels  obtained after 1 week of treatment will not differ from those 
obtained after 4 weeks of  treatment.  
2) To contrast  the effects  of CBD  to those  of placebo  on psychological  and cognitive  domains  relevant  to AUD  
and PTSD /subthreshold PTSD . Relative to placebo, we predict that CBD will improve self -report measures 
of craving,  anxiety,  mood, and self -efficacy, and improve cognitive function. We will also specifically target 
the domain  of traumatic  stress  induced  craving  using a human  laboratory  task.  We predict  that relative  to 
placebo,  CBD  will lead to a greater attenuation in subjective traumatic stress and alcohol cue -induced 
craving  and accompanying physiological stress  response.  
3) To assess  the effect  of CBD  on plasma  anandamide  levels.  We will contrast  levels  of plasma  anandamide  
between  samples  taken  at baseline  and after CBD  treatment,  and between  samples  taken  at predicted  pre- 
and [ADDRESS_63815]  that relative  to placebo,  CBD  will lead to an increase  
in plasma  anandamide  between these time  points.  
4) To assess  the temporal  relationship  between  the onset  in reduction of PTSD symptoms and the onset in 
reduction of AUD symptoms. We predict that a reduction  in PTSD symptoms will precede a reduction in 
Version :  4.3 #S17 -[ZIP_CODE]  
15  
 AUD  symptoms.  
Exploratory Aim 1:  To examine voicemarkers as a function of a patient’s AUD and PTSD status and to 
develop assessment models that use lexical and prosodic features to classify a patient’s AUD and PTS D 
status.  
 
4 Study Design and  Endpoints  
 
4.1 Description of Study  Design  
 
The proposed study is a phase I/II, single -center, double -blind, randomized proof -of-concept study  designed  to 
assess safety and feasibility in the AUD+PTSD /subthreshold PTSD  population and contrast effects of CBD 
treatment to  those  of placebo  on drinking -related  outcomes  and PTSD  symptoms.  We will evaluate  the safety  
of an extended  daily CBD treatment regimen in an AUD+PTSD /subthreshold PTSD  population, measure 
resulting  pla sma and CBD and  THC levels,  generate  preliminary  data on the impact  of CBD  on alcohol  
consumption  and PTSD  symptoms,  assess  the effect  of CBD  on a human  laboratory  measure  of traumatic -
stress  induced  craving  and neuropsychological measures  relevant  to  AUD  and  PTSD /subthreshold PTSD ,  
and  assess  the  effect  of  CBD  dosing  no plasma anandamide  levels.  
 
150 participants are expected to be enrolled in the study prior to screening and randomization. Following  
screening  and baseline  asses sments,  48 participants who fully meet study criteria  are expected to  be 
randomized  in a 5:3 ratio to receive  either  600mg CBD/day (PO) or placebo  respectively for 6 weeks (N=30 
participants on CBD and N=18 participants on placebo). This dose was selected to optimize anxiolytic affects 
to target stress induced alcohol  craving. Assessments  of drinking  and PTSD  related  outcomes  will be completed  
at baseline  and weekly  over 6 weeks  of treatment , with an assessment one week following the end of treatment.  
The human  laboratory  task and assessments  of cognitive  function  will be completed  at baseline  and at the end 
of 6 weeks  of treatment. Measurement of circulating levels of CBD, THC, and THC metabolites (Delta -9 THC, 
11-Hydroxy Delta -9 THC and Delta -9 Carboxy THC) will be obtained from CBD -treated participants at baseline, 
[ADDRESS_63816] dose of CBD 
vs. placebo. Anandamide levels will be obtained from both CBD - and placebo -treated participants at the 
aforementioned time -points.   
 
Outcomes  will include  drinking  outcomes;  PTSD  symptoms; responses  to personalized  trauma  and alcohol  
scripts  designed  to elicit stress - and cue-induced  craving  and anxiety; cognitive function; circulating levels of 
CBD, THC and anandamide and safety measures  (adverse events, cognitive and motoric function), and 
psychological domains relevant to AUD+PTSD /subthreshold PTSD  including  self- reported  craving,  depression,  
and anxiety  across  6 weeks  of treatment  and one week following the end of treatment.  
 
Voice -markers: High -fidelity audio recordings from in -person or remote sessions of clinical interviews will be 
collected at screening. The audio recordings will be encrypted and transferred via secure transfer methods to 
a HIPAA compliant specialized entity for quality control and voice -makers analyses. If the participant  gives their 
consent, the collected audio recording s will be used to examine voice -markers as a function of a patient’s AUD 
and PTSD status and to develop assessment models that use lexical and prosodic features to classify a 
patient’s AUD and PTSD status. All the reco rdings will be de -identified and labeled with a unique study code 
number for each participant in the study. Study personnel of the HIPAA compliant specialized entity receiving 
voice -marker data will not have access to link participants’ study code to any i dentifying information collected 
throughout the study. These personnel  will not be able to re -identify study participants associated with the 
respective data using the unique identifiers. If the recorded audio data has any identifying information 
embedded in the recordings, that information will be removed by [CONTACT_464], who will review each audio file 
and delete any PHI before the file is sent to the specialized lab. Once the files are received , the specialized lab 
will double check the data for any PHI a nd if found , this will be removed prior to the data being used.  
 
4.2 Study  Endpoints  
 
4.2.1  Primary Study Endpoints  
The primary  study  endpoint  for alcohol  use will be number  of drinks  per day assessed  by [CONTACT_58650] [ 78]. The primary study endpoint for PTSD symptoms will be the PCL -5 total score.   Safety  
will be assessed  by [CONTACT_58651], as well as weeks 2, 6, and 7 to assess the liver function during and after treatment 
Version :  4.3 #S17 -[ZIP_CODE]  
16  
 with study medication.  
4.2.2  Secondary  Study Endpoints Secondary Alcohol use  endpoints  
Secondary  efficacy  endpoints  are the percent  carbohydrate -deficient  transferrin  (CDT) ; the percentage  of heavy  
drinking  days  (four or more  drinks  for women  or five or more  drinks  for men per drinking  day) averaged  for each  
treatment  week;  weekly  average  severity  of alcohol  craving  assessed  by [CONTACT_58652]  
[79]; weekly  percentage  of very heavy  drinking  days  (8+/10+  drinks  per day for women  and men 
respectively);  weekly  percentage  of days  abstinent;  weekly  percentage  of subjects  with no heavy  drinking  days,  
and weekly percentage of subjects that are ‘present and clean’, i.e. present to provide breath alcohol  levels  
(BAC) and have a BAC of zero  [80]. 
 
AUD -related  measures  
The Penn  Alcohol  Craving  Scale  (PACS)  [79] will be used  to assess  craving.  This scale  has [ADDRESS_63817],  and discriminant  validity.  Self- 
efficacy will be assessed using the Alcoho l Abstinence Self -Efficacy Scale (AASE) [81], a self-report 
questionnaire  which  has been  used  widely  in the alcohol  treatment  research,  both as a predictor  of outcome  
and as a patient -treatment  matching  variable  [82]. Craving , self-efficacy, and alcohol use  will be assessed  
before treatment (baseline), week 1, week 4, week 6,  and at one week following the completi on of treatment. 
Mood and Anxiety will be measured with the Beck Anxiety Inventory (BAI) [99]  and Beck Depression Inventory -
II (BDI-II) [100]  scales  at baseline, treatment weeks 1, 4 and 6,  and at one week following treatment completion.  
 
Risk of suicidality will be assessed by a licensed study provider using the Columbia -Suicide Severity Rating 
Scale (C -SSRS)  [98] as part of each study visit.  
 
PTSD -related  measures  
The PCL -5 will be administered at baseline, weeks 2, 4, 6 and 7. In  additi on to the PCL-5 score  (primary  PTSD  
endpoint),  childhood trauma (child abuse and neglect) will be assessed at baseline using the self -report 
Childhood Trauma Questionnaire (CTQ) (28 item).  
 
Traumatic stress and cue response  task 
The Cue and Stress  Response  Task  will be performed  at the 4- week  time-point  using  methodology developed  
in Rajita  Sinha’s  lab, similar  to those  in used  in past studies  with alcohol  dependent  patients  [84]. [CONTACT_58728]  will 
provide  consultation  on the implementation  of these  methods.  Briefly,  imagery  scripts  will be developed  at 
baseline.  Traumatic  stress  imagery  scripts  will be based  on a recent  highly  stressful  traumatic  situation  the 
participant  has experienced  unrelated  to alcohol  use. Alcohol  cue scripts  will be derived  from a recent  event  
that included  alcohol -related  stimuli  and led to alcohol use. Neutral or relaxing scripts will also be developed. 
All scripts will be developed by  [CONTACT_58653],  including  contextual  details,  
cognitive  and verbal  content,  affective  experience,  and bodily  sensations.  These  details  form the basis  of a 5-
minute  imagery  script,  which  will be developed  for each  of the three  conditions.  Imagery  sessions  will be 
structured  with a 5-minute  pre-imagery  period, a 5 -minute imagery period, and a 5 -minute recovery period. 
Pulse, skin conductance, heart  rate variability, and blood pressure will be monitored during each image ry 
session with an  ADInstruments  PowerLab  4/30 Galvanic  Skin Response  device  and a Contec  Patient  Monitor.  
In Human  laboratory  studies with CBD, skin conductance and amygdala activation were reduced by [CONTACT_58654] a 
closely correlated  manner [ 52], suggesting  threat -related  sympathetic  arousal  may serve  as a proxy  for 
amygdala  activation  [53]. 
 
Participants will complet e Likert scale ratings of vividness, craving, anxiety, and the 30 -item Differential  Emotion 
Scale [ 84] following each of the three periods. After each condition, a progressive  relaxation procedure will be 
implemented to facilitate return to baseline of vital signs, craving and anxiety,  an approximate  period  of 10 
minutes , as shown  in previous  research  from the Sinha  lab [84]. The entire  imagery  protocol will take 120 
minutes. The order of the sessions will be randomized and counterbalanced  among  participants . The task will 
be completed at T6 (the end of 4 weeks  of treatment  with 600mg  daily).  At this point,  we expect  steady -state 
plasma  CBD  levels  to have  been  reached.   
 
Plasma CBD, THC and anandamide  levels  
Measurement of circulating levels of CBD, THC, Delta -9 THC, 11 -Hydroxy Delta -9 THC  and Delta -9 Carboxy 
THC will be obtained from CBD -treated participants at baseline (pre -CBD levels), followin g 45 minutes (T1 - 
Version :  4.3 #S17 -[ADDRESS_63818] -CBD levels),  1 day (T2 - 45min post -CBD levels),  1 week (T3 - 45min post -CBD and pre -CBD levels),  
2 weeks (T4 - 45min post -CBD and pre -CBD levels), 4 week s (T6 - 45min post -CBD and pre -CBD levels) ,6 
week s (T8 - 45min post -CBD and pre -CBD levels), and 7 weeks (T9 - pre-CBD levels) after  the first CBD vs. 
placeb o dose . Anandamide levels will be obtained from both CBD - and placebo -treated participants  at the 
aforementioned timepoints. All three levels (CBD, THC and anandamide) will be determined via  High 
Performance  Liquid  Chromatography/Tandem  Mass  Spectrometry  (LC-MS/MS)  by [CONTACT_58655].  
 
Psychomotor and subjective effects of  CBD  
Basic motoric and cognitive function will be evaluated throughout treatment with several established  field 
sobriety  tests,  including  a walk-and-turn task, one-leg stand , Romberg’s  test, finger -finger  test, and counting  
backwards  [85]. The Addiction  Resource  Center  Inventory  (ARCI),  49-item version  [86], will be used  as a 
measure  of the intoxicating  effects  and abuse  potential  of CBD.  Breath  Alcohol  Concentration  (BAC)  will also 
be measured  to ensure  participants  are not under  the influence  of alcohol  during  administration  of these  tasks.  
 
Cognitive  Function  
Several established neuropsychiatric and cognitive tasks will be administered to evaluate the impact of  CBD  
vs. placebo  treatment  on cognitive  domains  potentially  affected  by [CONTACT_58656]/or  THC.  The Rey Auditory  Verbal  
Learning  Task  (RAVLT)  will be used  to assess  epi[INVESTIGATOR_58589]  [87], the Mental  Rotation  Task  (MRT)  will 
evaluate visuospatial ability [ 88, 89], a Time Rep roduction Task (TRT) will measure encoding and retrieval  of 
time intervals [ 67] and  several  WM Span  tasks  (OSpan,  RSpan,  SymSpan,  RotSpan)  will measure  working  
memory capacity  [90, 91]. Cognitive  function  will be measured  at day 1 (T2)  and at the end of treatment  (T8).  
 
[ADDRESS_63819]  meet  all of the following  criteria:  
 
1. Males and females age  18-70 
2. DSM -5 diagnosis of moderate or severe  AUD  
3. DSM -5 diagnosis of PTSD with Clinician Administered PTSD Scale (CAPS -5) OR subPTSD diagnosis 
(meeting criterion A, F, G, H and at least 6 symptoms across any criteria B -E) with Clinician Administered PTSD 
Scale (CAPS -5) 
4. Able to provide voluntary informed  consent  
5. At least  4 heavy  drink ing days  (4 or more  drinks per day  for a woman,  5 or more  drinks  per day for a 
man)  in the 30 days prior to  screen  
6. If of childbearing potential (male or female), are willing to use approved form of contraception from screening 
for duration of the trial 
7. Able to provide at least two locators  
8. Endorse desire to cut down or stop drinking  
9. Agrees to abstain from all other cannabinoid use for the duration of the study  
10. Confirms they are reliably domiciled  
 
5.2 Exclusion Criteria  
An individual  who meets  any of the following  criteria  will be excluded  from participation  in this study:  
1. Current alcohol withdrawal (CIWA -Ar score  >7) 
2. Exclusionary medical conditions (e.g. current severe alcohol withdrawal requiring  medical hospi[INVESTIGATOR_059], 
significantly impaired liver  function)  
3. DSM -5 diagnosis of schizophrenia, schizoaffective disorder, bipolar  disorder  I 
4. High risk of adverse emotional or behavioral reaction, and/or an inability to understand study procedures or 
the informed consent process,  based on investigator’s clinical evaluation (e.g., evidence of serious personality 
disorder, antisocial behavior, serious current stressors, lack of meaningful social support)  
5. Exposure to trauma in the last 30 days, including police duty or military servi ce 
6. Current significant suicidality (assessed using the C -SSRS), any significant suicidal behavior in the past 12 
months, or any history of serious suicide attempts requiring hospi[INVESTIGATOR_059], or current significant homicidality  
7. History of Severe Traumatic B rain Injury (TBI; as indicated by [CONTACT_58657] > 24 hours)  
8. DSM -5 diagnosis of current mild cannabis use disorder and/or moderate or severe substance use disorder 
for a substance other  than alcohol or  nicotine  
Version :  4.3 #S17 -[ZIP_CODE]  
18  
 9. Significant laboratory abnormalities, including significantly impaired liver function, serious abnormalities of 
complete blood count or metabolic panel  
10. Active legal problems likely to result in incarceration within 12 weeks of treatment  initiation  
11. Pregnancy or lactation  
12. Current use of exclusionary medications, including cannabinoids; treatments for addictions including  alcohol;  
moderate to strong inhibitors of CYP3A4 or CYP2C19; medications metabolized primarily by  [CONTACT_097]3A5  or 
CYP3A7;  and medications  with a narrow  therapeut ic index  which  are substrates  of CYP3A4, UGT1A9,  UGT2B7, 
CYP2C8, CYP2C9, CYP2C19, CYP1A2, or  CYP2B6.  
13. Current treatment for AUD ( with exceptions of : AA/12 -step treatment and/or psychosocial treatment initiated 
more than 2 months prior to the screening visit)  
14. Current treatment for methadone or opi[INVESTIGATOR_2554]  
15. Psychotherapy for PTSD or other psychiatric condition, if initiated within [ADDRESS_63820] with subjects through multimodal 
outreach including contacts with treating clinicians in medical and psychiatric clinics at the Cohen Vete ran Center 
(600 recruited annually) and Military Family Clinic at NYUMC (500 enrolled annually); Manhattan VA, Bronx, 
Manhattan and Brooklyn VA PTSD clinics and other VA medical centers within the greater [LOCATION_001] City area 
(over 1300 with PTSD and comorbi d AUD); Women’s Mental Health Consortium of NY, Derner Institute at 
Adelphi University;  addiction services sites, including the detox unit and Chemical Dependency Outpatient 
Program at Bellevue (11,400 visits annually, combined), Psychiatry Outpatient Clin ic and Primary Care Clinic at 
Bellevue hospi[INVESTIGATOR_307], addiction services at the Manhattan and Brooklyn VA, and at the Federally Qualified Health 
Center (FQHC), an outpatient psychiatry clinic at NYU Lutheran Medical Center (115,000 visits annually).  
Additionall y, patients will be recruited at the Nathan Kline Institute/Rockland Psychiatric Center and Gouverneur 
Health.  Fliers and brochures will be distributed by [CONTACT_58658].  
 
Clinicians will be asked to only refer individua ls who they believe are appropriate for the study, can safely delay 
treatment for [ADDRESS_63821] info rmation , and relevant clinical i nformation for interested patients, who 
will sign an authorization form allowing the clinic to release their relevant information to study staff . Once referrals 
are given, the study team will access EPIC to determine the participant’s initial eligibility. [CONTACT_58729] and the 
study coordinators will maintain relationships with clinicians at these institutions in order to generate referrals . 
Additionally, the study team will use NYU’s DataCore service to gather information from EPIC for current NYU 
patients wh o may be eligible. Participants can be referred to the study by [CONTACT_9682], the clinic, or through 
DataCore reports. To gather the information from EPIC, DataCore will request a report. Data gathered will be 
used to identify subjects that did not opt out of being contact[CONTACT_33632], and who fit eligibility criteria for this 
study. The data gathered will include inclusionary and exclusionary criteria, including the following information:  
 
Inclusion Criteria:  
-18-70 years old  
WITH diagnosis of PTSD (Post Traumatic Stress Disorder) OR Acute Stress Disorder OR Adjustment Disorder 
AND Alcoholism OR Alcohol Use Disorder OR Alcohol Abuse WITHOUT a diagnosis of Schizophrenia OR 
Version :  4.3 #S17 -[ADDRESS_63822] this information from  EPIC monthly. Once a patient  has been deemed potentially eligible 
for the study, and is also noted in EPIC as having consented to be contact[CONTACT_33632], approved staff  will 
e-mail potential participants’ treating physicians following scheduling the pa tient for their assessment visit. 
Approved staff will contact [CONTACT_58659], MyChart, or by [CONTACT_648]. 
Due to sharing the same recruitment resources, the phone consent and screen will be identical to those used 
in [CONTACT_58730]’s study, s18 -[ZIP_CODE] . Any recruitment information sent by [CONTACT_58660] 
(or will be done through MyChart). Once contact [CONTACT_58661], approved recruitment language will be used to 
communicate the reason for contact [CONTACT_58662]. If the potential participants  agree, the study team will provide with information regarding 
the next steps for participation. If a participant requests informat ion regarding opting out of further recruitment 
for all research, they will be directed to contact [CONTACT_2296].  
 
Active recruitment will also take place through social me dia sources, including Facebook, Twitter, Instagram , 
Reddit,  Craigslist,  clinical trial p re-screening services like StudyKik, Patient Wise, BuildClinical, and TrialFacts,  
online research recruitment sites such as ResearchMatch, VolunteerMatch ClinicalConnection, Antidote, and 
TrialSpark, online forums, local newspapers and other print media (i .e. Bushwick Daily, Queens Chronicle, New 
York Post, Schneps Media etc.), online periodicals such as Time Out Magazine, Military Times and Schneps 
media, radio advertisements within [LOCATION_001] City, online targeted advertisement services from companies such 
as the Washington Post, email newsletters such as Division of Veteran Services,  through academic email 
listservs (including Child and Adolescent Mental Health Studies [CAMS] listserv),  at social service agencies, 
community mental health clinics, community  organizations, local professional organizations, residential 
treatment facilities, consenting support and recovery centers, regional employee assistance programs, religious 
organizations, cultural centers, social clubs,  local shops,  and local universities . Fliers and brochures will be 
distribu ted by [CONTACT_58658]. Additionally, the study team will use NYU’s 
DataCore service to gather information from EPIC for current NYU patients who may be eligible.  
 
TrialFacts: TrialFa cts is a referral service that targets advertisements to individuals who may be eligible for the 
study. Participants are provided with detailed information about the study and then complete a brief IRB -
approved questionnaire. Participants who complete the questionnaire have consented to collection of their 
responses to the questionnaire, including their contact [CONTACT_3031], as well as TrialFacts’ sharing their information 
with the study team. Trialfacts provides the study team with the respondents’ question naire responses and 
contact [CONTACT_3031] (name, phone number, email, state, zip code, gender, and DOB) if they meet minimum 
eligibility requirements via a restricted access spreadsheet. If not eligible, TrialFacts releases the questionnaire 
responses but no t the respondents’ contact [CONTACT_3031]. The study team may request ineligible respondents’ 
contact [CONTACT_58663] -check on responses on an as needed basis.  
 
Eligible, participants are invited to book an appointment for the phone scr een using the TrialFacts online platform. 
If they do not book an appointment, the study team reaches out to the participant to schedule.  If the participant 
chooses to book online, they are sent a calendar invitation and a confirmation email.With an online  booking, 
TrialFacts sends the participant email reminders 24 hours and 1 hour before their phone screen appointment, 
and text message reminders 1 hour and 10 minutes before the phone screen appointment.  
 
After the study team completes the phone screen, the restricted access spreadsheet is updated with participant’s 
enrollment status and/or reason for exclusion in order to help TrialFacts better target audiences. The study team 
only indicates whether the participants was enrolled or not enrolled a nd which of the exclusion criteria were met. 
The reasons for exclusion on the spreadsheet are limited to: not enough drinking days; current life stressors; 
exclusionary medication; exclusionary medical condition; exclusionary psychiatric disorder; exclusio nary 
treatment; drug use; no PTSD; age; scheduling; new treatment; unwilling to use contraceptives; recent trauma; 
behavioral concerns; and legal issues. No identifiers or health information  are added to the spreadsheet.  
 
Potential participants can either  call the study line directly to speak with research staff or they can follow the 
link to a study screening questionnaire located at the bottom of the flyers and ads. The link re -directs to a 
secure, RedCap survey. Potential participants will indicate that  they consent to complete the survey 
electronically before completing the questionnaire. Staff will contact [CONTACT_58664], email, and/or text message. Respondents will indicate their preferred method of contact  [CONTACT_58665].   
 
BuildClinical: BuildClinical is an advertising and referral service that targets advertisements to individuals 
Version :  4.3 #S17 -[ZIP_CODE]  
20  
 who may be eligible for the study. Study advertisements will be developed, IRB approved, and then 
optimally deployed across web platforms to target and engage the study population via the BuildClinical 
patient advertising network. Individuals who click on a BuildClinical ad will be redirected to a brief IRB 
approved REDCap questionnaire. BuildClinical provides the study team with the respondents’ questionnaire 
responses and contact [CONTACT_3031] (name, phone number, email, and state) if they meet minimum elig ibility 
requirements via a HIPAA compliant internet portal. The internet portal is a one -way transfer of information 
from BuildClinical to the study team. The study team will not share any additional information with 
BuildClinical. All BuildClinical ads wi ll be submitted to the IRB for approval prior to use.  
 
All potential participants will be asked to complete a brief pre -screening interview either in person or by 
[CONTACT_756], using an IRB approved, and scripted pre -screening form describing the basic facts  of the study and 
inquiring about inclusion and exclusion criteria.  (See request for waiver of authorization and waiver of 
documentation of consent). Study staff conducting the screening may ask follow -up questions or use the 
Timeline Followback tool to clarify responses and assess eligibility. An abridged version of the LEC (Life Events 
Checklist ) will be completed during the pre -screening interview. Participants who pass the pre -screening 
interview (i.e., those who appear likely to qualify for the study a nd remain interested in participating) will be 
scheduled for a screening visit.   
 
Individuals  that do not pass the pre -screening or decline to enroll in the study  will be asked whether they would 
like their information retained so they can be contact[CONTACT_58666]. Participants may also opt -
in to being re -contact[CONTACT_58667]/or AUD symptoms are near the inclusion 
threshold. If they decline , all information collected will be de -identified and all PHI information will be destroyed 
at the end of the study . The s tudy team will have no linking information for those who fail the pre -screen or 
decline participation. If they assent to re -contact, PHI data collected on the initial screening form will be retained 
only for and shared with NYU -affiliated researchers strictly for the purpose of re -contact[CONTACT_58668].  
 
Participants in [CONTACT_58729]’s clinical trial “Leveraging Biom arkers for Personalized Treatment of AUD Comorbid 
with PTSD” (IRB # s18 -[ZIP_CODE]) who are determined to be ineligible will be evaluated for eligibility in this trial. 
Consenting participants’ data will be linked to this study and procedures completed under th e Biomarkers trial 
will not be duplicated for this trial except at PI [INVESTIGATOR_5768] -Investigator discretion.  
 
Based on successful recruitment in current and past AUD and PTSD trials at NYULMC, we do not expect any 
significant barriers to recruitment. If recruitme nt lags, strategies would include altering staffing patterns and 
increasing advertisement and outreach to clinical programs. To maximize rates of completion of the follow -up 
visit, we will follow procedures that have been successful in retaining patients w ith similar demographics, e.g. 
drug using emergency department patients, for whom we have achieved follow -up rates of 85% at 6 months. If 
follow -up rates at 10 weeks are below 90%, we will reexamine our tracking procedures, and consider altering 
the reimbu rsement and/or completing community -based follow -ups. 
 
We expect the population to be approximately 50% male, 50% female; 7% Hispanic, 60% Non -Hispanic 
Caucasian, 30% Non -Hispanic African American, and 3% other.  
 
5.[ADDRESS_63823]  during  these  9 weeks  is estimated at 30 -35 hrs. 
 
5.6 Total Number of Participants and Sites  
Recruitment  will end when  approximately  150 participants  are enrolled.  It is expected  that approximately  48 
participants who fully meet study criteria  will be randomized in  a 5:3 ratio to receive  either  600mg CBD/day (PO) 
or placebo  respectively (N=30 participants on CBD and N=18 p articipants on placebo) . 
 
5.[ADDRESS_63824].  An investigator  may 
terminate participation in the study  if: 
• Any clinical  adverse  event  (AE),  laboratory  abnormality,  or other  medical  condition  or situation  occurs  
such that continued participation in the study would not be in the best interest of the  participant  
Version :  4.3 #S17 -[ZIP_CODE]  
21  
 • The participant  meets  an exclusion  criterion  (either  newly  developed  or not previously  recognized) that 
precludes further study  participation  
• The participant fails to adhere to protocol  requirements  
 
5.7.2  Handling of Participant Withdrawals or  Termination  
Every  effort  will be made  to undertake  the protocol -specified  safety  follow -up procedures  to capture  AEs,  SAEs,  
and UPs.  The investigator  will attempt  to obtain  at a minimum  safety/ survival  data on all participants  lost to 
follow -up. If a participant  is lost to follow -up, they study  team  will attempt  to contact  [CONTACT_58669] [ADDRESS_63825] to follow -up prior to the end of the 6-week  treatment  phase  
(prior  to T8), they will not be replaced  to maintain 48 randomized  participants  to complete  the 6-week  treatment  
phase  (through  T8) and their partial data will be handled according to the statistical analysis plan (SAP) . 
 
5.[ADDRESS_63826]. Marmar,  NIH/NIAAA,  the FDA,  the DEA,  and the NY State  BNE.  If the 
study is prematurely terminated or suspended, the PI [INVESTIGATOR_58590](s) 
for the termination or  suspension. Circumstances  that may warrant  termination  or suspension  include,  but are 
not limited  to: 
 
• Determination of unexpected, significant, or unacceptable risk to  participants  
• Demonstration of efficacy that would warrant  stoppi[INVESTIGATOR_007]  
• Insufficient compliance with protocol  requirements  
• Data that are not sufficiently complete and/or  evaluable  
 
Study  may resume  once  concerns  about  safety,  protocol  compliance,  data quality  are addressed  and satisfy 
the sponsor, IRB and/or  FDA.  
 
6 Study Agent (Study drug, device, biologic, vaccine etc.)  and/or  
Procedural  Intervention  
6.1 Study Agent(s) and Control  Description  
The TN -C200M2 Oral Capsules and matching placebo for this study are provided by [CONTACT_58670]. The CBD is 
derived from cannabis and processed according to CGMP standards (see Quality Overall Summary document 
provided by [CONTACT_58671]). The active capsules will include CBD (the active ingredient) at a quantity of 200mg per 
capsule, as well as a mix of surfactants, co -surfactants, co -solvents and carrier oils. The placebo capsules will 
only include the same excipi[INVESTIGATOR_840], with no CBD.  
 
6.1.[ADDRESS_63827], 
Nanaimo, British Columbia, Canada V9X 1J2. The IND & DEA schedule I researcher, Michael P. Bogenschutz, 
MD, will acquire a [LOCATION_001] State Bureau of Narcotic Enforcemen t Class [ADDRESS_63828] to be used in this study (TN -C200LM Oral Capsule) is a formulation of CBD dissolved in a 
mix of surfactants, co -surfactants, co -solvents and carrier oils at a concentration of 400mg/g. The formulation 
is des igned to act as a self -emulsifying drug delivery system (SEDDS). Hard gelatin size -zero capsules are 
filled with the formulation to a fill weight of 500mg, providing a single capsule dose of 200mg CBD. This product 
in investigational and will be acquired a s described above in 6.1.1. The TN -C200M2 Oral capsules are 
packaged in pharmaceutical grade 100mL polyethylene terephthalate (PET) bottles and lid, with a fill of 20  
capsules.  
Version :  4.3 #S17 -[ADDRESS_63829] Storage and  Stability  
The study  drug,  CBD,  will be stored  securely  by [CONTACT_58672]’s individual  schedule  1 DEA 
registration  and [LOCATION_001] Bureau  of Narcotics  Enforcement  (BNE)  class  [ADDRESS_63830]  be reassayed  at 9-months.  The Principal  Investigator  [INVESTIGATOR_58591],  accountability  and dispensing  of the study  medication  and all study  drug administration  to the patients  
will be done by [CONTACT_978] [INVESTIGATOR_58592]-investigators.  
 
Tilray TM has provided  stability  data for RSM -CBD  Lots P56/8/116,  P56/8/116,  p56/17/017  and P56/44/[ADDRESS_63831] two batches and 9 -months  data 
has been generated on the second two batches. There is no evidence of degradation for any of the  samples 
stored at 4, 25 and 40 degrees Celsius after 9 -months. Additional and detailed stability data can be found  in 
the accompanying Quality Overall Summary (QOS)  document.  
 
6.1.[ADDRESS_63832] is going to be shipped and received in its  ready -for-dispensation 
formulation,  there  will not be any preparation  required  prior to dispensation.  The study  drug will be dispensed  
by [CONTACT_58673].  
 
6.1.5  Dosing and  Administration  
Participants  will self-administer  CBD  vs Placebo  twice  daily for a total of 600mg/day  CBD  vs. Placebo  for  six-
week s. Participants  will self-administer  two 200mg  capsules  every  morning  following  a light  meal  at 
approximately  the same  time of day, and an additional  single  200mg  capsule  approximately  12 hours later 
following a light  meal.  
 
6.1.6  Route of  Administration  
CBD  will be administered  orally  in capsules  that each  contain  200mg  CBD  vs. Placebo.  
 
6.1.7  Starting Dose and Dose Escalation Schedu le 
All participants  will receive  600mg/day  CBD  vs. Placebo  for weeks  1-6 of treatment  (T1-T8), unless  
contraindicated.  
 
6.1.8  Dose  Adjustments/Modifications/Delays  
If participants  report  AEs that are determined  by [CONTACT_978] [INVESTIGATOR_58593] -related  during  administration  of study 
medication and are intolerable to the participant or represent a significant risk to the participant,  daily 
administration will be reduced by 200mg/day every two days until symptoms are tolerable or  clinical 
abnormalities are resolved.  For self -described symptoms, tolerability will be determined by a joint  decision  
between  the PI [INVESTIGATOR_58594],  based  upon  of whether  this symptom  is tolerable  or treatment  related.  For 
laboratory abnormalities, all values outside of the normal range will be regarded as presenting a risk,  as 
evaluated  by [CONTACT_978]. All reported  AEs will be recorded.  Dose  will be titrated  back  up toward  the full dose  by 200 
mg/day/week  as tolerated,  based  upon  a repeat  assessment  by [CONTACT_978], including  laboratory  tests.  
 
Individuals who cannot tolerate the 600mg dose will remain on their maximum tolerable dose for  the remainder  
of the study.  Treatment  will be discontinued  immediately  if continuing  the medication  places  the participant  at 
significant  risk in the medical  judgement  of the PI.  
 
6.1.[ADDRESS_63833]  complete  the 6- 
week treatment phase of the study (through to  T8). 
 
6.2 Study Agent Accountability  Procedures  
CBD will be stored by [CONTACT_58674]’s individual schedule 1 DEA registration  and 
[LOCATION_001] Bureau of Narcotics Enforcement (BNE) class 7 license in accordance with all applicable laws  and 
Version :  4.3 #S17 -[ADDRESS_63834], C -D Building 4th floor, [LOCATION_001], NY [ZIP_CODE]. The Primary Investigator will oversee the  appropriate  
storage,  accountability  and dispensing  of the study  medication  and all study  drug administration  to the patients  
will be done  by [CONTACT_978] [INVESTIGATOR_58592]-investigators.  In order  to preserve  the blind,  medication  will be administered  
in identical  capsules  containing  0 or 200 mg of CBD  dissolved  in a mixture of self -emulsifying ex cipi[INVESTIGATOR_840];  
participants  will be delivered  multiple 200mg capsules/day for a total of 0 or600 mg  CBD/day.  
 
Study  medication  will be received  under  a Schedule  [ADDRESS_63835] supervision of the 
PI [INVESTIGATOR_1660] a designated coinvestigator, as approved by [CONTACT_58675].  Participants  will be required  to return  
all un-used  medication,  which  will be kept securely  at the drug storage  site until it is sent to a reverse  
distributor  for destruction.  
 
Designated  study  personnel  will keep  a log of the study  drug accountability  and dispensing  in accordance  with 
[LOCATION_001] State  Bureau  of Narcotic  Enforcement  and DEA policies  (see below).  This process  will provide  strict 
safeguarding  and accounting  of the agent  both for internal  and external  regulatory  agencies.  
 
As per Schedule I drug compliance, a biennial inventory shall be prepared and maintained in accordance  with 
[LOCATION_001] State  and federal  statutes.  A copy  of the inventory  will be kept on file with other  controlled  substance 
records  and shall be kept available  for inspection  for at least  5 years.  The number  of study  drug-containing  
capsules will be checked on a weekly basis by [CONTACT_58676] 
a Controlled  Substance  Accountability  Log which  includes  the following  information:  1) date and time of 
recording, 2) name [CONTACT_58726], 3) amount received (number of capsules), 4) amount  dispensed,  
and 5) amount  returned.  All other  information  will be included  in the Study  Drug  Dispensation  Log as each  
individual  subject's  dose  is dispensed.  The information  included  in the Study  Drug  Dispensation  Log is: 1) 
subject  initials/number  (plus  date of birth as a double  identifier),  2) date and time of study  drug dispensation,  3) 
drug name,  4) lot number,  and 5) dose.  Two designated  study  team  members  will sign the Study  Drug  
Dispensation Log. The balance of the remaining medication and any amount returned will be recorded in the  
Controlled Substance Accountability Log (see  above).  
 
6.3 Study Behavioral or Social  Intervention(s)  
All participants  will receive  Medical  Management by a licensed MD or NP,  based  on the model  developed  for 
the NIAAA  COMBINE  trial [92]. This model  provides  a low intensity  intervention  that has some  efficacy  over no 
intervention,  and is designed to enhance compliance in the context of a clinical trial. Brief counselling sessions 
provided by  a licensed MD or NP focus  on: support  for recovery,  treatment  participation,  reporting  possible  
adverse  effects,  and medication compliance. The co -investigator [CONTACT_58731] has experience adapting 
this model in a  prior alcohol pharmacotherapy trial  [93]. 
 
6.3.1  Administration of  Intervention  
CBD (or placebo) will be administered daily for [ADDRESS_63836] administration of CBD vs. placebo (at  T1) will 
take place at the study site . Participants will remain at the study site with a study team member  for 
approximately  [ADDRESS_63837] (a walk-and-turn task, 
one-leg stand , Romberg’s  test, finger -finger  test, and counting  backwards  [85]). If there  are no AEs during  this 
time-period  or lasting  intoxicating  effects  of the study  drug (i.e. participants  are able to pass  field sobriety  tests  
2-3 hours  after study  drug administration),  participants  will be given  a 1- or 2-week  supply  of the study  drug 
(CBD or placebo) to self -administer daily at home until the next scheduled study  visit. 
 
6.3.[ADDRESS_63838] Compliance with Study  Intervention  
To maximize medication compliance, we will implement an optional smartphone -assisted medication  
adherence  platform  [94] in which  the subject  takes  a video  of drug administration  at each  dose,  and transmits  
this to study personnel. This program has been used successfully in previous studies and includes  security 
provisions that ensure protection of confidentiality and  privacy. If the participant is unable to use the 
smartphone -assisted platform then medication adherence wi ll be ensured using pi[INVESTIGATOR_58595].  
Version :  4.3 #S17 -[ZIP_CODE]  
24  
  
7 Study Procedures and Schedule  
7.1 Study Procedures/Evaluations  
 
Inclusion/exclusion  criteria:  
Medical screening  by [CONTACT_58677], liver function tests, 
complete blood  count , urinalysis, menstrual calendar (if female except those menopausal for >[ADDRESS_63839] menstrual period and/or had a bilateral oophorectomy ), pregnancy test (if f emale except those 
menopausal for >[ADDRESS_63840] menstrual period, had a hysterectomy, and/or had tubal  ligation), and vital 
signs for safety. The licensed provider (NP or MD) will also review participants’ controlled substance 
prescription history usi ng the online Prescription Monitoring Program (PMP) Registry to inform study 
eligibility. The Structured Clinical Interview for DSM -5 (SCID )  will be used  to determine  substance  use 
disorder  diagnoses  and exclusionary  psychiatric  disorders {First, 1997 #114}. The Life Events Checklist 
(LEC)  and Clinician Administered PTSD Scale (CAPS)  for DSM 5 will be used to assess  PTSD  symptoms 
[101]. The Concussion Symptom Inventory  (CSI)  and a modified version of the Ohio State University TBI 
Identification Method (TBI OHIO)  will be used to assess for Traumatic Brain Injury (TBI). The clinical interviews 
will be conducted by [CONTACT_58678], masters -level study team members and 
bachelors -level study team members with suff icient psych -assessment training as approved by [CONTACT_9154]. 
Individuals will have the option to be audiotaped during the screening interview. If the participant consents, 
audio recordings  will be used to ensure quality control and clinical adherence to the protocol. Audio 
recordings will also be used for voice -marker analysis . If a participant voices that he/she is uncomfortable 
with the audiotaped interview, he/she can tell a study team member that he/she does not wish to participate 
in this component of  the study. In that case, the participant could still participate in the study but would not 
complete the audiotaped interview.  
 
PhenX Tier [ADDRESS_63841]  information,  
demographics,  BMI,  quality  of life, HIV risk and status,  and substance  use measures  (age of onset, past 
30-day quantity and frequency, lifetime use for alcohol, tobacco, and other  substances;  
www.phenxtoolkit.org). The Clinical  Institute  Withdrawal  Scale - Alcohol,  revised  (CIWA -Ar) will be used  to 
verify lack of alcohol withdrawal [ 95], a urine drug screen (UDS) will be done at every in -person st udy visit 
(except for visits less than [ADDRESS_63842] visit; i.e. 1 day visit) to verify lack  of recent cannabinoid 
and other drug use, and a urine pregnancy test  will be done at each in -person study visit (for women of 
childbearing potential : if female except those menopausal for >[ADDRESS_63843] menstrual period, had a 
hysterectomy, and/or had tubal ligation ) to verify lack of pregnancy . If subjects are found to have suicidal 
intentions based on screening  tests, appropriate referrals to mental health professionals will be made by [CONTACT_1600]. 
 
7.1.1  Confirmation of target CBD plasma levels and measurement of THC levels:  
Circulating  levels of CBD, THC and THC metabolites  (Delta -9 THC, 11 -Hydroxy Delta -9 THC  and Delta -9 
Carboxy THC) will be obtained from CBD -treated participants baseline (pre -CBD levels), followin g 45 minutes 
(T1- 45min post -CBD levels),  1 day (T2 - 45min post -CBD leve ls), 1 week (T3 - 45min post -CBD and pre -CBD 
levels),  2 weeks (T4 - 45min post -CBD and pre -CBD levels), 4 week s (T6 - 45min post -CBD and pre -CBD 
levels) ,6 week s (T8 - 45min post -CBD and pre -CBD levels), and 7 weeks (T9 - pre-CBD levels) after  the first 
CBD vs. placeb o dose . All of these levels (CBD, THC and THC metabolites) will be determined via  High 
Performance  Liquid  Chromatography/Tandem  Mass  Spectrometry  (LC-MS/MS)  at [CONTACT_58732]’s Lab at 
the Department of  Cell Biology at NYU Langone Health. . 
 
7.1.2  Measurement of plasma Anandamide levels:  
Plasma  AEA levels  will be obtained  at baseline (pre -CBD levels), followin g 45 minutes (T1 - 45min post -
CBD levels),  1 day (T2 - 45min post -CBD levels),  1 week (T3 - 45min post -CBD and pre -CBD levels),  2 weeks 
(T4- 45mi n post -CBD and pre -CBD levels), 4 week s (T6 - 45min post -CBD and pre -CBD levels) ,6 week s (T8 - 
45min post -CBD and pre -CBD levels), and 7 weeks (T9 - pre-CBD levels) after  the first CBD vs. placeb o dose . 
Plasma  AEA levels  will be determined  via High  Performanc e Liquid Chromatography/Tandem Mass 
Spectrometry (LC -MS/MS) at [CONTACT_58732] ’s Lab at the Department of  Cell Biology at NYU Langone 
Health . 
 
7.1.3  Safety:  
Version :  4.3 #S17 -[ZIP_CODE]  
25  
 Safety will be assessed by [CONTACT_58679] (SAFTEE)  [103]  measure at all visits after treatment is initiated. LFTs will be obtained at 
screening, as well as weeks 2, [ADDRESS_63844], or C -SSRS certified  study 
team member using the Columbia -Suicide Severity Rating Scale (C -SSRS ) [98]  as part of each study visit, 
including screening and baseline. If the pati ent endorses significant suicidality/homicidality ,  a safety 
assessment will be conducted, referrals provided, and if indicated, a case report form will be written  if indicated,  
a follow -up phone call within [ADDRESS_63845] the overall study PI (Charles Marmar, MD) for further consultation.  
The appropriate procedures for all study team members to follow in the case of a psychiatric or medical 
emergency are outlined in detail in the Medical and Psychiatric Emergencies SOP.  
 
7.1.4  Psychomotor and subjective effects of CBD:  
Basic  motoric  and cognitiv e function  will be evaluated  throughout  treatment  with several  established  field 
sobriety tests, including a walk-and-turn task , one-leg stand , Romberg’s test , finger -finger test , and counting  
backwards  [85]. The Addiction  Resource  Center  Inventory  (ARCI) , 49-item version  [86], will be used  as a 
measure  of the intoxicating  effects  and abuse  potential  of CBD.  Breath  Alcohol  Concentration  (BAC)  will 
also be measured  to ensure  participants  are not under  the influence  of alcohol  during  administration  of these  
tasks.  
 
7.1.5  Cognitive Function:  
Several established neuropsychiatric and cognitive tasks will be administered to evaluate the impact of CBD 
vs. placebo  treatment  on cognitive  domains  potentially  affected  by [CONTACT_58656]/or  THC.  The Rey Auditory  
Verbal  Learning  Task  (RAVLT)  will be used  to assess  epi[INVESTIGATOR_58589]  [87], the Mental  Rotation  Task  
(MRT)  will evaluate  visuospatial  ability  [88] [89], a Time  Reproduction  Task  (TRT)  will measure  encoding  
and retrieval of time intervals [ 67] and several  WM Span  tasks  (OSpan,  RSpan,  SymSpan,  RotSpan)  will 
measure  working  memory  capacity  [90, 91]. Cognitive  function  will be assessed  one day after  CBD  or 
placebo  treatment and at 6 weeks following  treatment.  
 
7.1.6  AUD -related measures:  
The Penn Alcohol Craving Scale (PACS) [79] will be used to assess craving. This scale has [ADDRESS_63846],  and discriminant  validity.  
Craving will be assessed before CBD or placebo treatment (baseline), at weeks 1, 4 and 6 of treatment, and 
one week after the completion of treatment (week 7).  Mood  and Anxiety will be measured with the Beck Anxiety 
Inventory (BAI) [99]  and Beck Depression Inventory -II (BDI-II) [100]  scales before CBD or placebo treatment 
(baseline), at weeks 1, 4 and 6 of treatment, and one week after the completion of treatment (week 7).  Self-
efficacy  will be assessed using the Alcohol Abstinence Self -Efficacy Scale (AASE) [81], a self-report  
questionnaire  which  has been  used  widely  in the alcohol  treatment  research,  both as a predictor  of 
outcome  and as a patient -treatment  matching  variable  [82]. Self-efficacy  will be assessed  before  CBD  or 
placebo  treatment (baseline),  at weeks 1, 4 and 6 of treatment, and one week after the completion of treatment 
(week 7).  
 
7.1.7  PTSD -related measures:  
PTSD  symptoms  will be assessed  with the PTSD checklist for  the DSM -5 (PCL -5) [96]. Baseline  PTSD  
symptoms  will be defined  as the total PCL-5 score  at baseline.  The primary  PTSD  outcome  is the total score  of 
the PCL -5 for each week administered. PTSD symptoms will be assessed before CBD or placebo treatment 
(baseline),  at weeks 2, 4 and 6 of treatment, and one week after the completion of treatment (week 7).  
 
7.1.8  Cue and Traumatic Stress Response Task  
The Cue and traumatic stress Response Task will be performed using methodology developed in  Rajita 
Sinha’s  lab, similar  to that in used  in past studies  with alcohol  dependent  patients  and AUD+PTSD /subthreshold 
PTSD  patients  [84].. Imagery  scripts will  be developed  at baseline.Traumatic  stress  imagery  scripts  will be based  
on a recent  highly  stressful situation that the participant identifies as traumatic. Alcohol cue scripts will be 
derived fro m a recent event  that included  alcohol -related  stimuli  and led to alcohol  use. Neutral  or relaxing  
scripts  will also be developed.  All scripts  will be developed  by [CONTACT_58680],  including  contextual  details,  cognitive  and verbal  content,  affective  experience,  and bodily  sensations.  
These  details  form the basis  of a 5-minute  imagery  script,  which  will be developed  for each  of the three  
conditions.  Imagery  sessions  will be structured  with a 5-minute  pre-imagery  period,  a 5-minute  imagery  
period,  and a 5-minute  recovery  period.  Pulse,  skin conductance,  heart  rate variability,  and blood  pressure  
Version :  4.3 #S17 -[ZIP_CODE]  
26  
 will be monitored  during  each imagery session with an ADInstruments PowerLab 4/30 Galvanic Skin Response 
device and a  Contec  Patient  Monitor.  In Human  laboratory  studies  with CBD,  skin conductance  and 
amygdala  activation  were  reduced by [CONTACT_58654] a closely correlated manner [ 52], suggesti ng threat -related 
sympathetic arousal may  serve as  a proxy  for amygdala  activation  [53]. Participants  will complete  Likert  scale  
ratings  of vividness,  craving, anxiety,  and the 30-item Differential  Emotion  Scale  [84] following  each  of the three  
periods.  After  each  condition, a  progressive  relaxation  procedure  will be implemented  to facilitate  return  to 
baseline  of vital signs, craving  and anxiety,  an approximate  period  of 10 minutes,  as shown  in previous  research  
from the Sinha  lab [97]. The entire  imagery  protocol  will take [ADDRESS_63847] been  
reached.  
 
7.1.9  Alcohol use:  
Alcohol consumption will be assessed with a constellation of measures from Time -line Follow -back  (TLFB)  
[78], percent carbohydrate -deficient transferrin (CDT) , and breath alcohol concentration (BAC).  
 
 
7.2 Laboratory and Voice -markers Procedures/Evaluations  
Plasma  will be collected  at baseline  before  treatment,  and [ADDRESS_63848] - and pre-dosing  levels  of CBD,  according  
to the study’s SOP.  Briefly,  we will measure  plasma  CBD , THC and THC metabolite  levels  at baseline, 45 
minutes,  1 day, 1 week, 2 weeks,  4 weeks,  6 weeks,  and 7 weeks  after treatment  with CBD.   Plasma  (1ml/sample)  
will be stored  at -20 °C for no longer  than 6 months,  and will be labeled  with study  number,  participant  number,  
and timepoint  as specified  in the MOP.   Plasma CBD levels will be determined via High Performance Liquid 
Chromatography/Ta ndem  Mass Spectrometry (LC -MS/MS) by [CONTACT_58681]. Thomas Neubert Lab at the 
Department of  Cell Biology at NYU Langone Health .  
 
7.2.2  Specimen Shipment  
Specimens  will be shipped  monthly  on dry ice with appropriate  labeling  for shipment  of biological  specimens on  
dry ice, according  to the study’s  MOP.  Medical  screening  labs will be labelled  according  to CTSI  protocols  and 
processed  by [CONTACT_46147].   Plasma for  anandamide , CBD, THC and THC metabolite testing  will be sent to [CONTACT_58733]  laboratory   at the Department of Cell Biology at NYU Langone Health.  A specimen  tracking  log will be 
utilized  to record  dates  and times  that each  specimen  was collected  and shipped.  Specimens  may be shipped  
overnight  or walked to [CONTACT_58734] lab between  9:00am  and 5:00pm on business days .  
 
7.2.3 Voicemarkers Procedure  
Voice -markers: Clinical interviews (in -person and remote) will be audio and/or video -taped to ensure quality 
control and clinical adherence. De -identified audio recordings of participants who  consent to participate in the 
voice -markers analysis will be encrypted and sent via secure sites to HIPAA compliant labs for analysis.  
 
7.2.[ADDRESS_63849] the voice -markers analysis; any authorized  entity will only receive de -identified data without any PHI 
or linking information and will store the data on secure servers.  
 
No individual identities will be used in any reports or publications resulting from the study. Study information, 
such as the digital audio recordings will be coded with a code number unique to the study. Only authorized 
Version :  4.3 #S17 -[ADDRESS_63850] access to the files that links 
the identifying information and study ID codes. Digital audio recordings of interviews will be encrypted and 
pass -code protected while retained on a secure NYU server until the  conclusion of the study; at that point they 
will be deleted. Only the investigator and study personnel will have access to the digital audio recordings in 
order to compare the ratings on the standardized interview format. Sessions will be recorded digital ly. All files 
will be secured using a digital encryption key. No unauthorized persons will be able to access this key to open 
the audio files. These encrypted audio files will be de -identified , stored and password protected on a secure 
server. Any identif ying information embedded in the audio recordings will be deleted during the transcription 
process. Any data sharing will follow all the NYU data security requirements. Identifiable data will not be stored 
on laptops, PDA’s, flash drives or other portable devices.  De -identified data will be shared via mailed encrypted 
CDs, encrypted emails, or via a VPN access and secure access to the secure NYU server.  
 
7.3 Study  Schedule  
 
 
Version :  4.3 #S17 -[ZIP_CODE]  
28  
  
 
 

Version :  4.3 #S17 -[ZIP_CODE]  
29  
 
 

Version :  4.3 #S17 -[ZIP_CODE]  
30  
  
7.3.1  Screening  Visit (S1) (2 Options)  
 
Option 1: Screening Visit – In-Person  
• Adminis ter consent quiz  (up to 2 administrations)  and obtain informed consent of potential participant 
verified either by [CONTACT_58682].  
• Obtain consent of participant on audio/visual consent form , either by [CONTACT_58683]/visual 
consent form or through electronic signature.  
• Perform alcohol breathalyzer to obtain BAC  
• Review medical and family to determine eligibility based on inclusion/exclusion  criteria  
• Perform psychiatric assessments to determine eligibility based on inclusion/exclusion criteria  
• Audio -record clinical interview (if participant consents to this component) to ensure clinical quality 
control , and study voice -markers for participants that consent to voice -marker analysis . Audio 
recordings can be waived per PI [INVESTIGATOR_9106].  
• Review concurrent medications to determine eligibility based on inclusion/exclusion  criteria  
• Perform medical examinations needed to determine eligibility based on inclusion/exclusion  criteria  
• Obtain demographic information, contact [CONTACT_3031], alcohol, drug, and tobacco use  history and 
quality of life  
• Collect urine for urine drug analysis, urinalysis, urine pregnancy  test (if applicable)  
• Collect blood  at either the One Park site or at  CTSI  for hepatic function panel/ liver function tests  (LFT) , 
complete blood count  with differential , basic metabolic panel, and serum pregnancy test  (if female)  
• Record vital signs  
• Schedule study visits for participants who are eligible and available for the duration of the  study  
 
NOTE: The in -person screening visit may be split into two or more sessions to accommodate participants’ 
schedules, provider availability, etc. All portions of the screening visit must be complete within 1 month.  
 
Option 2: Screening Visit – Two-part: Clinical Screen  Remote; Medical Screen  In-Person  
To reduce participant burden and minimize in -person screening visits, we will offer participants the option of 
splitting the screening visit into two or more sessions. Th e first session will be completed remotely (phone or 
WebEx) to establish that minimal inclusion criteria and no exclusion criteria are met. Participants will be invited to 
a second session, which will be completed in -person, if they meet minimum inclusion/ exclusion criteria standards. 
All portions of the screening visit must be complete within 1 month.   
 
Session 1: Clinical Screen – Remote  
• Administer consent quiz  (up to 2 administrations)  and obtain informed consent of potential participant 
verified either by [CONTACT_58684] 
. 
• Obtain consent of participant on audio/visual consent form, verified either by [CONTACT_58683]/visual 
consent form or through electronic signature . 
• Review medical and family history to determine eligibility based on inclusion/exclusion criteria  
• Perform psychiatric assessments to determine eligibility based on inclusion/exclusion criteria  
• Revie w concurrent medications to determine eligibility based on inclusion/exclusion criteria  
• Obtain demographic information, contact [CONTACT_3031], alcohol, drug, and tobacco use history and 
quality of life  
 
Session 2 – In Person  
• Perform alcohol breathalyzer to o btain BAC  
• Review medical and family history  
• Perform medical examinations needed to determine eligibility based on inclusion/exclusion criteria  
• Collect urine for urine drug analysis, urinalysis, urine pregnancy test (if applicable)  
• Collect blood at either t he One Park site or at CTSI for hepatic function panel/ liver function tests 
(LFT), complete blood count with differential, basic metabolic panel, and serum pregnancy test (if 
female)  
• Assess withdrawal using CIWA -Ar 
• Record vital signs  
• Schedule study visits  for participants who are eligible and available for the duration of the study.  
 
Version :  4.3 #S17 -[ZIP_CODE]  
31  
  
7.3.2  Enrollment/Baseline (B1)  (Day 0, 1 -30 days after Screening Visit)  
• Perform alcohol breathalyzer to obtain BAC  
• Record vital signs, results of examination, other assessments, concurrent medications and menstrual 
calendar (if applicable)  
• Record AUD -related and PTSD related  measures  
• Collect imagery scripts for the cue/traumatic stress response task  
• Collect urine for urine drug analysis and urine pregnancy test (if a pplicable)  
• Collect baseline plasma for baseline CBD, THC, and AEA levels (pre -CBD dosing levels)  
• Collect blood for carbohydrate deficient transferrin (CDT) test  
• Record results of evaluations of safety and psychomotor  effects and AUD, PTSD related domains  
• Record adverse events as reported by [CONTACT_58685]  
• Evaluate and record alcohol  use 
• Administer medical management  session  
• Provide participants with study medication to administer at visit  
• Provide participants with sufficien t study medication to administer daily until the next scheduled visit (1 
week), and instructions for how to use the study medication and document their use  
 
7.3.3  Intermediate Visits  
Intermediate visits that do NOT include safety labs may be conducted remotely via phone or WebEx .  
 
[IP_ADDRESS]  Visit 3  
45 minutes +/- 10 minutes  (T1) 
• Collect blood and plasma for CBD, THC, and AEA levels at [ADDRESS_63851]  medication (post -CBD 
levels)  
• Record adverse events as reported by [CONTACT_58685]  
• Result s of evaluations of safety, and psychomotor  effects  
• Record participant’s adherence to treatment  program  
 
[IP_ADDRESS]  Visit 4 (1 day  after Baseline/Enrollment  Visit  +5 days ) 
1 day (T2 ) 
• Perform alcohol breathalyzer to obtain BA C 
• Collect blood and plasma for CBD, Delta -9 THC, 11 -Hydroxy Delta -9 THC, Delta -9 Carboxy THC and 
Anandamide levels ([ADDRESS_63852] -CBD levels) . 
• Collect urine for urine drug analysis  
• Record adverse events as reported by [CONTACT_58685]  
• Record vital signs, concurrent medications, and results of evaluations of safety, cognitive function and 
psychomotor  effects  
• Record participant’s adherence to treatment  program  
• Evaluate and record alcohol  use 
 
[IP_ADDRESS]  Visit  5   
1 week  (T3) 
+/- 5 days  
• Perform alcohol breathalyzer to obtain BA C  
• Collect urine for urine drug analysis and urine pregnancy test (if applicable)  
• Collect blood and plasma for CBD, Delta -9 THC, 11 -Hydroxy Delta -9 THC, Delta -9 Carboxy THC and 
Anandamide levels (post - and pre -CBD d osing levels)  
• Record adverse events as reported by [CONTACT_58685]  
• Record vital signs, concurrent medications, menstrual calendar (if applicable ), and results of 
evaluations of safety, psychomotor/subjective  effects  
• Evaluate and rec ord AUD related measures  
• Evaluate and record alcohol  use 
• Provide participants with sufficient study medication to administer daily until the next scheduled visit (1 
week), and instructions for how to use the study medication and document their use  
• Record p articipant’s adherence to treatment  program  
• Administer medical management  session  
 
Version :  4.3 #S17 -[ZIP_CODE]  
32  
 [IP_ADDRESS]  Visit 6  
2 weeks  (T4) 
+/- 5 days  
• Perform alcohol breathalyzer to obtain BA C  
• Collect urine for urine drug analysis and urine pregnancy test (if applicable)  
• Collect blood and plasma for CBD,  Delta -9 THC, 11 -Hydroxy Delta -9 THC, Delta -9 Carboxy THC and 
Anandamide levels (post - and pre -CBD levels)  
• Collect blood for liver function tests (LFT)  
• Record adverse events as reported by [CONTACT_58685]  
• Record vital signs, concurrent medications, menstrual calendar (if applicable ), and results of 
evaluations of safety, psychomotor/subjective  effects  
• Evaluate and record alcohol  use 
• Evaluate PTSD -related  measures  
• Provide participants with suffi cient study medication to administer daily until the next scheduled visit (2 
weeks), and instructions for how to use the study medication and document their use  
• Record participant’s adherence to treatment  program  
• Administer medical management  session  
 
[IP_ADDRESS]  Phone call  1 
3 weeks  (T5) 
+/- 5 days  
• Record adverse events as reported by  [CONTACT_3445]  
• Record participant’s adherence to treatment  program  
• Record concurrent medications, menstrual calendar (if applicable ), and results of evaluations of safety  
 
[IP_ADDRESS]  Visit  7 
4 weeks  (T6) 
+/- 5 days  
• Perform alcohol breathalyzer to obtain BA C  
• Collect urine for urine drug analysis and urine pregnancy test (if applicable)  
• Collect blood, plasma and serum for CBD, Delta -9 THC, 11 -Hydroxy Delta -9 THC, Delta -9 Carboxy 
THC and Anandamide levels (post - and pre -CBD levels)  
• Collect blood for carbohydrate deficient transferrin (CDT) test  
• Record adverse events as reported by [CONTACT_58685]  
• Record v ital signs, concurrent medications, menstrual calendar (if applicable ), and results of 
evaluations of safety, psychomotor/subjective  effects  
• Evaluate and record alcohol  use 
• Evaluate and record AUD and PTSD -related  measures  
• Administer the cue/traumatic stress response task and record  response  
• Provide participants with sufficient study medication to administer daily until the next scheduled visit (2 
weeks), and instructions for how to use the study medication and document their use  
• Record pa rticipant’s adherence to treatment  program  
• Administer medical management  session  
 
[IP_ADDRESS]  Phone call  2 
5 weeks  (T7) 
+/- 5 days  
• Record adverse events as reported by [CONTACT_3445]  
• Record participant’s adherence to treatment  program  
• Record concurrent medications, menstrual calendar (if applicable ), and results of evaluations of safety  
 
[IP_ADDRESS]  Visit  8 
6 weeks (T8)  
+/- 5 days  
Version :  4.3 #S17 -[ZIP_CODE]  
33  
 • Perform alcohol breathalyzer to obtain BAC  
• Collect urine for urine drug analysis and urine pregnancy test  (if applicable)  
• Collect blood, plasma and serum for CBD,  Delta -9 THC, 11 -Hydroxy Delta -9 THC, Delta -9 Carboxy 
THC and Anandamide levels (post - and pre -CBD levels)  
• Collect blood for carbohydrate deficient transferrin (CDT) test and liver function tests (L FT) 
• Record adverse events as reported by [CONTACT_58685]  
• Record  vital signs,  concurrent medications, menstrual calendar (if applicable ), and results  of evaluations  of 
safety,  psychomotor/subjective  effects  
• Evaluate and record alcohol  use 
• Evaluate and record AUD and PTSD -related  measures  
• Collect information for cognitive  function  changes  
• Provide participants with morning dose of study medication  at the study visit and 1 pi[INVESTIGATOR_58596].   
• Record participant’s adherence to treatment  program  
• Administer medical management  session  
 
[IP_ADDRESS]  Visit  9 
7 weeks (T9)  
+/- 5 days  
• Perform alcohol breathalyzer to obtain BAC  
• Collect urine for urine drug analysis and urine pregnancy test  (if applicable)  
• Collect blood and plasma for CBD,  Delta -9 THC, 11 -Hydroxy Delta -9 THC, Delta -9 Carboxy THC and 
Anandamide levels (pre-CBD levels)  
• Collect blood for liver function tests (LFT)  
• Record adverse events as reported by [CONTACT_58685]  
• Reco rd vital signs, concurrent medications, menstrual calendar (if applicable), results of evaluations of 
safety, psychomotor/subjective  effects   
• Evaluate and record alcohol  use 
• Evaluate and record AUD and PTSD -related  measures  
 
7.3.4  Final Telephone Follow -Up 
9 weeks (T10)  
+/- 5 days  
• Record adverse events as reported by  [CONTACT_3445]  
• Evaluate and record alcohol  use 
• Record evaluations of safety  
• Administer treatment completion questionnaires  
 
7.3.5  Unscheduled  Visit  
Unscheduled  visits  will be documented  on an unscheduled  visit form.  
 
7.3.6  Clinical Re -Screen  
If there is a delay of ~2 -3 months between an eligible participant’s screening visit and baseline visit, the following 
measures/procedures will be administered during a “clinical re -screen” at a  separate visit or completed on the 
same day as the baseline visit (prior to baseline procedures) to confirm continued study eligibility as applicable:  
 
The following measures/procedures will be conducted at the clinical re -screen:  
• BAC 
• Urine toxicology screen and urine pregnancy test (if applicable)  
• PCL-5 (past month)  
• TLFB (past 30 days)  
• CIWA -Ar 
• CSSRS (since last visit)  
• Current medications  
Version :  4.3 #S17 -[ZIP_CODE]  
34  
 • Vital signs  
• If determined necessary by [CONTACT_58686], we may c ollect urine for urine analysis and blood at 
either the One Park site or at CTSI for hepatic function panel/ liver function tests (LFT), complete blood 
count  (CBC) with differential , basic metabolic panel, and serum pregnancy test (if female)  
 
If there is a delay of over 3 months between an e ligible participant’s screening visit and their baseline visit, then 
the specific measures/procedures listed above (with the exception of the CSSRS since last visit) will be re -
administered. The LEC/CAPS5, CSSRS baseline/screening, and relevant sections of  the SCID5 will also be re -
administered to confirm continued study eligibility and to confirm previously collected data. The TBI Ohio/CSI 
form will also be updated with any new head injuries.  Re-screen procedures will be conducted remotely except 
blood dra ws and urine analysis, if applicable.  
7.4 Concomitant Medications, Treatments, and  Procedures  
All concomitant  prescription  medications  taken  during  study  participation  will be recorded  on the case  report 
forms  (CRFs).  For this protocol,  a prescription  medication  is defined  as a medication  that can be prescribed  only 
by a properly authorized/licensed clinician. Medications to be reported in the CRF are  concomitant prescription  
medications,  over-the-counter  medications  and non-prescription  medications.  
7.5 Prohibited Medications, Treatments, and  Procedures  
Treatment with medications acting on serotonergic pathways,  cannabinoids,  treatments  for addictions  including  
alcohol,  and medications  metabolized  primarily  by [CONTACT_097]3A4,  CYP3A5,  or CYP3A7  will not be permitted  unless  
discussed  with and approved  by [CONTACT_978]. 
 
8 Definitions of Key Terms  
An adverse event  (AE; also referred to as an adverse e vent) is any untoward medical occurrence associated with 
the use of a drug (pharmaceutical investigational product) in humans, which does not necessarily have a causal 
relationship with that treatment. An AE can therefore be any unfavorable and unintended sign (e.g., an abnormal 
laboratory finding or test result), symptom, disease, accident, or worsening (increase in severity or frequency) of 
a pre -existing abnormality, temporally associated with the use of the drug, whether or not considered related to 
the drug. An AE can arise from any use of the drug (e.g., off -label use, use in combination wi th another drug and 
from any route of administration, formulation, or dose, including overdose).  
A serious adverse event (SAE)  is an adverse drug or biologic or device experience occurring during any study 
phase (i.e., screening, admission, treatment, or follow -up), and at any dose of the study drug, comparator or 
placebo, that results in one or more of the following criteria:  
• Results in death  
• Is life -threatening*  
• Requires in -patient hospi[INVESTIGATOR_059] (i.e., admission) or prolongation of existing hospi[INVESTIGATOR_059]  
• Results in persistent or significant disability** or incapacity  
• Is a congenital abnormality or birth defect (in an offspr ing) 
• Is an important medical event that may not result in death, be life -threatening, or require or prolong 
hospi[INVESTIGATOR_12475], based upon appropriate medical judgment, the event 
may jeopardize the subject or may require medical or surgical intervention to prevent one of the outcomes 
listed above. Examples of important medical events include events requiring intensive treatment in an 
emergency department, convulsions that do not require in -patient hospi[INVESTIGATOR_059], or the developme nt of 
drug dependency or drug abuse (see Section 8, Other Significant Adverse Events).  
*Life-threatening:  Any AE that places the subject, in the view of the investigator, at immediate risk of death from 
the reaction as it occurred; it does not include a re action that, had it occurred in a more severe form, might have 
caused death.  
**Disability:  A substantial disruption of a person’s ability to conduct normal life functions.  
 
Version :  4.3 #S17 -[ZIP_CODE]  
35  
 9 Specification of Safety Variables  
Safety and toxicity monitoring will be performed throughout the study for all subjects. Safety variables to be 
assessed include AEs, vital signs, and safety laboratory values, when collected.  
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and interviews 
of a study participant presenting for medical care, or upon review by a study monitor. At each study visit following 
screening, designated study team members will inquire about the occurrence of AE/SAEs since the last visit.  
 
[ADDRESS_63853] all AEs, regardless of 
causality or severity, with start dates occurrin g any time after informed consent is obtained until 7 (for AEs) or 30 
(for SAEs) days after the last day of study participation on the AE case report forms (CRF). Information to be 
collected includes event description, time of onset, clinician’s assessment  of severity, relationship to study product 
(assessed only by [CONTACT_8703] a diagnosis), and time of resolution/stabilization 
of the event.  
Any medical condition that is present at the time that the participant is screened  will be considered as baseline 
and not reported as an AE. However, if the study participant’s condition deteriorates at any time during the study, 
it will be recorded as an AE.  
Changes in the severity of an AE will be documented to allow an assessment of  the duration of the event at each 
level of severity to be performed. AEs characterized as intermittent require documentation of onset and duration 
of each epi[INVESTIGATOR_1865].  
At the last scheduled visit, the CRC should instruct each subject to report any subsequent event(s) . 
10.1 Solicitati on of AEs  
At all follow -up visits occurring after study medication has been administered, the SAFETEE questionnaire 
[Johnson et al., 2005] will be used to assess AEs . The presence or absence of specific AEs should not be solicited 
from subjects.  
10.[ADDRESS_63854] has a hospi[INVESTIGATOR_29918] (e.g., elective surgery) that was due to a 
preexisting condition that has not worsened since enrollment in the study (i.e., since the subject [or the subject’s 
legal representation] signed the informed consent), the hospi[INVESTIGATOR_58597] a therapeutic 
intervention and not the results of an AE. However, if the event/condition worsens during the study,  it must be 
reported as an AE (or SAE, if the event/condition results in a serious outcome, such as hospi[INVESTIGATOR_059]).  
10.3 Reports of Cancer  
Cancer is no longer considered an FDA criterion for an SAE (unless an event occurs with a serious outcome). If 
a new dia gnosis of cancer has a serious outcome, then the reporting time frame for an SAE (48 hours) must be 
met. Progression of disease is not considered new cancer and is therefore not an AE.  
10.[ADDRESS_63855] be reviewed to determine if it 
meets the criteria for an SAE.  
11 Assessment of Adverse Events  
Version :  4.3 #S17 -[ZIP_CODE]  
36  
 The followi ng definitions, developed in accordance with the US Code of Federal Regulations (CFR) and the 
International Committee on Harmonization (ICH), will be used for the purpose of identifying AEs in this clinical 
study.  
11.1 Expectedness  
Unexpected : An AE is consider ed unexpected if it is not listed in the Investigator Brochure (IB) or is not listed at 
the specificity or severity that has been observed, or not previously observed in animal toxicity studies for 
psilocybin. Unexpected also refers to AEs that are mention ed in the IB as occurring with a class of drugs or as 
anticipated from the pharmacologic properties of the drug, but are not specifically mentioned as occurring with 
psilocybin.  
11.[ADDRESS_63856] be made with the appropriate invo lvement of a medically qualified investigator. 
The investigator will evaluate the severity of each AE using the following three terms and definitions:  
• Minimal:  single occurrence that is not distressing and does not limit activities  
• Mild:  multiple occurrenc es, awareness of sign or symptom but easily tolerated, usually does not require 
intervention or limit activities  
• Moderate:  discomfort sufficient to cause interference with normal activities; intervention may be needed  
• Severe:  incapacitating, with inability  to perform normal activities; treatment or other intervention usually 
needed  
11.[ADDRESS_63857] 
is suspected, check “No.” The following reasons  for possible relationship to drug are to be assessed by [CONTACT_58687].  
• Dose -response:  indicates that the intensity of the event is related to the dosage level.  
• Timing of onset:  is used if the onset of the event has some regular relationships to drug administration 
(e.g., it always occurs 1 hour after taking the drug).  
• Known drug effect:  is another reason for suspecting a drug relationship.  
The relationship of each AE to study drug will be assessed using the following terms and definitions:  
• Probable (must have first two) : This category applies to AEs that are considered, with a high degree o f 
certainty, to be related to the study drug. An AE may be considered probable, if:  
o It follows a reasonable temporal sequence from administration of the drug.  
o It cannot be reasonably explained by [CONTACT_20612]’s clinical state, 
environmental or toxic factors, or other modes of therapy administered to the subject.  
o It follows a known pattern of response to the suspected drug.  
• Possible:  This category applies to those AEs in which the connection with the study drug administrat ion 
is possible. An AE may be considered possible if, or when,  any of the above reasons have been selected.   
• Unrelated : This category is applicable to those AEs that are judged to be due only to extraneous causes 
(e.g., disease, environment, etc.) and do n ot meet any of the criteria for a possible drug relationship.  
The determination of the relationship of the AE to the use of the study drug(s) rests on careful medical 
consideration of the PI.  
[ADDRESS_63858] to follow -up. Relevant 
Version :  4.3 #S17 -[ADDRESS_63859]’s 
source documentation.  Follow -up laboratory results should be filed with the subject’s source documentation.  
For all AEs that require the subject to be discontinued from the study, relevant clinical assessments and laboratory 
tests will be repeated as clinically appropriate, un til final resolution or stabilization of the event(s).  
 
[ADDRESS_63860] that serious AEs are likely in clinical studies. Refer to the IB for toxicology 
findings and information  on AEs observed to date.  
 
14 Other Significant Adverse Events  
Should any AE occur that is considered significant, but does not meet the criteria for an SAE, the CRC and PI 
[INVESTIGATOR_58598].  
 
15 Reporting Procedures  
15.1 AE Reporting  
To the FDA: In accordance with FDA reporting requirements, all AEs occurring during the course of the clinical 
trial will be collected, documented, and reported by [CONTACT_978] [INVESTIGATOR_58599]. On an annual basis, as part of the 
update to the study IND, the IND Sponsor will subm it to the FDA:  
• A list of all AEs that have occurred during the reporting period  
• A summary of all IND safety reports submitted during the past year  
• A list of all subjects who died during the participation in the investigation, listing cause of death for ea ch,  
• And a list of subjects who dropped out during the course of the investigation in association with any 
adverse experience, whether or not thought to be drug related.  
To the IRB: In accordance with local IRB requirements, all AEs occurring during the co urse of the clinical trial 
regardless of relationship to study activities will be collected, documented, and reported by [CONTACT_978] [INVESTIGATOR_58600] o n an annual basis  in the application for the study’s continuation renewal. Staff education, re -training or 
appropriate corrective action plan will be implemented when unreported or unidentified AEs or SAEs are 
discovered, to ensure future identification and timely reportin g.  
To the DSMB:  All AEs occurring during the course of the clinical trial regardless of relationship to study activities 
will be reported to the DSMB at regular meetings. Prior to each DSMB meeting, the PI [INVESTIGATOR_58601] a report to the 
Board including revi ew of aggregate analysis of AEs and SAEs.  
Following each meeting, the board will provide the PI [CONTACT_4490] a report including a recommendation to continue the 
study unchanged, continue with modifications of the protocol and/or the consent form to protect partici pant safety, 
or terminate the study. This report will then be submitted to the FDA as part of the annual report to the study IND, 
and the IRB in the application for the study’s annual continuation renewal.  
To the Study Sponsors:   
Tilray  
The PI [INVESTIGATOR_58602]. 
The PI [INVESTIGATOR_58603] y associated CRFs and source data, safety reports related to such AEs and SAEs, 
Version :  4.3 #S17 -[ZIP_CODE]  
38  
 and permit access to anonymized pharmacokinetic data of study subjects.  
PI [INVESTIGATOR_58604] (e.g. annually for the duration of  the trial, 
including prior to enrollment of the first participant, following completion of treatment for the first [ADDRESS_63861] 20 completers, and upon completion of enrollment for the trial).   
NIH/NIAAA  
All AE s occurring during the course of the clinical trial regardless of relationship to study activities will be collected, 
documented, and reported by [CONTACT_978] [INVESTIGATOR_58605]/NIAAA on an annual basis in the annual Research 
Performance Progress Report (RPPR).  
15.2 SAE Reporting  
SAEs will be promptly reported to the CRC and PI. The PI [INVESTIGATOR_58606] (SAEs) from Adverse Events (AEs). The details of the event will be documented and reported as follows:  
To the FDA: The PI i s required to report certain study events in an expedited fashion to the FDA. These written 
notifications of AEs are referred to as IND/IDE safety reports.  
The following describes the IND safety reporting requirements by [CONTACT_58688]:  
• Within 7 calendar days (via telephone or facsimile report)  
Any study event that is : 
– associated with the use of the study drug  
– unexpected, and  
– fatal or life -threatening  
 
• Within 15 calendar days (via written report)  
Any study event that is : 
– associated with the use of the study drug,  
– unexpected, and  
– serious, but not fatal or life -threatening  
-or- 
– a previous AE that was not initially deemed reportable but is later found to fit the criteria for reporting 
(reporting within 15 calendar days from when event was deemed reportable).  
Any finding from tests in laboratory animals that:  
– suggest a significant risk for human subjects including reports of mutagenicity, teratogenicity, or 
carcinogenicity.  This is not applicable for us as we are not using animals in this study.  
Each written notification must be submitted on an FDA Form 3500A . The PI [INVESTIGATOR_58607].  
To the IRB: The IRB Chair or Administrator will be notified immediately  for SAEs that are at least possibly related 
to study participation only. If the IRB administrator determines that reporting of the incident/issu e is required, it will 
be submitted to the IRB within 48 hours of the IRB direction/response .  
The team will also submit summary information related to all SAEs, AEs, and UPs in the annual application for 
continuation to the IRB.  
To the Study Sponsors:  
NIH/NIAAA  
SAEs considered at least possibly related to study participation will be documented and reported to NIAAA within 
48 hours  with copi[INVESTIGATOR_58608]’s file.  
Tilray  
If an SAE occurs after the subject signs info rmed consent through the end of study participation, the PI [INVESTIGATOR_1660] a 
qualified designee will complete the Tilray SAE Form and send it via email to contacts designated by [CONTACT_58689] :  4.3 #S17 -[ADDRESS_63862] be completed a nd submitted to Tilray any time a 
serious medical event has occurred in a participant during the clinical trial, whether or not it is considered related 
to the study treatment, including active comparators and placebo.  
Ensure that an investigator has revie wed and signed the SAE form prior to submission.  
Every exposure during pregnancy (participant) should be reported on an SAE worksheet as a case of special 
interest from the time of study enrolment to the end of study participation.  
The following timelines describe when Tilray, as the manufacturer of IP, has to report ADRs to Health Canada:  
• Fatal or life -threatening unexpected ADRs require notification of regulatory agencies as soon as possible 
but no later than [ADDRESS_63863] knowledge by [CONTACT_58690] a case qualifies, followed by [CONTACT_58691] a report as possible within 8 additional calendar days. The report will include an assessment of 
the importance and implication of the findings, including relevant previous experience with the same or 
similar medicinal products.  
• All other serious, unexpected ADRs must be filed as soon as possible but no later than [ADDRESS_63864] knowledge by [CONTACT_58692].  
15.3 UP Reporting  
Incidents or event s that meet the OHRP criteria for UPs involving risks to subjects or others require notification of 
the local IRB. The phrase “unanticipated problems involving risks to subjects or others” is found but not defined 
in the HHS regulations at 45 CFR part 46. Any incident, experience, or outcome that meets  all of the following 
criteria is considered to be Reportable New Information (RNI) and is required to be promptly reported to the local 
IRB: 
• unexpected  (in terms of nature, severity, or frequency) given (a) t he research procedures that are 
described in the protocol -related documents, such as the IRB -approved research protocol and informed 
consent document; and (b) the characteristics of the subject population being studied;  
• related or possibly related  to parti cipation in the research (in this guidance document,  possibly 
related  means that, in the opi[INVESTIGATOR_17439], the incident, experience, or outcome was more likely than not 
caused by [CONTACT_58693]); and  
• suggests that the research places subjects or others at a greater risk of harm  (including physical, 
psychological, economic, or social harm) than was previously known or recognized.  
OHRP recognizes that it may be difficult to determine whether a particular incident, experience, or outcome is 
unexpected and whether it is related or possibly related to participation in the research. OHRP notes that an 
incident, experience, or outcome that meets the three criteria above generally will warrant consideration of 
substantive changes in the researc h protocol or informed consent process/document or other corrective actions 
in order to protect the safety, welfare, or rights of subjects or others.   
The RNI report will include the following information:  
• Protocol identifying information: protocol title a nd number, PI’s name, and the IRB project number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome represents 
an UP;  
• A description of any cha nges to the protocol or other corrective actions that have been taken or are 
proposed in response to the UP.  
UPs must be reported using the following timeline:  
• UPs that are SAEs will be reported to the IRB and to the study sponsor according to SAE reporting 
procedures described above (within 48 hours of the investigator becoming aware of the event ). 
• UPs that meet the requirements for RNI will be reported to the IRB as soon as possible and within 5 
working days of the site becoming a ware of the event . 
Version :  4.3 #S17 -[ZIP_CODE]  
40  
 • All other UPs not related to study activities or that do not result in harm to participants will be reported to 
the IRB annually  in the application for the study’s continuation renewal.  
15.[ADDRESS_63865] becoming aware of the pregnancy.  
Tilray Pregnancy Reporting Requirements : Every exposure during pregnancy (participant) should be reported on 
a Tilray SAE worksh eet within [ADDRESS_63866] 
from the time of study enrollment to the end of study participation. If an SAE occurs in conjunction with the 
pregnancy, then the Tilray reporting timeframe for a n SAE (24 hours) must be met. In the event of a pregnancy, 
administration of study medication will be discontinued, but all other follow -up data, including safety data, will be 
collected.  
Pregnancies resulting in congenital abnormalities or birth defects i n offspring meet the requirements for an SAE 
and will be collected, documented, and reported according to the procedures outlined above for SAEs.  
 
[ADDRESS_63867] (defined as a pharmaceutical form of an 
active substance or placebo being tested or used as a reference in a clinical trial) must be reported by [CONTACT_978] [INVESTIGATOR_58609] [ADDRESS_63868] quality 
complaint.  
16.2 Temperature Deviations  
In the event that the temperature at which the IP is stored is less than 2°C or greater than 8°C , the CRC and PI 
[INVESTIGATOR_58610] a temperature deviation form will be completed and sent via emai l to contacts 
designated by [CONTACT_58694]. Tilray will provide further guidance on how to proceed on a case -by-
case basis.  
 
17 Study Halting  Rules  
When three  severe  AEs are  determined  to be “probably  related”  to the study agent, the DSMB will be informed 
and asked to convene in order to determine whether action should be taken.  The Principal Investigator  [INVESTIGATOR_58611]  24 hours  of this occurrence  and will provide  the DSMB  with AE listing  reports.  
The DSMB  will convene  an ad hoc meeting  by [CONTACT_58695].  The DSMB will 
provide recommendations for proceeding with the study to the Principal Investigator. The   Principal Investigator 
[INVESTIGATOR_58612]’s decision and the disposition of the study. If  the DSMB  finds  it is likely  that 
CBD  is contributing  to negative  outcomes,  they will consider  solutions  including  protocol  changes  or potentially  
stoppi [INVESTIGATOR_10098].  
 
18 Safety  Oversight  
The research team (project manager, coordinators,  and research  assistants)  will submit  any adverse  events  to 
the PI [INVESTIGATOR_58613] (DSMB).  The PI [INVESTIGATOR_58614] (SAEs) reported. All SAEs will  be reviewed at the time they are 
reported in the electronic data capture system. Where further information  is needed, the DSMB will discuss the 
Version :  4.3 #S17 -[ADDRESS_63869]  (DSMB)  
A Data  and Safety  Monitoring  Board  (DSMB)  will be established,  comprising  three  to five individuals  appointed  
by [CONTACT_978]. The committee  will include  [CONTACT_58735],  [CONTACT_58736] and [CONTACT_58737]. This committee 
will meet (in person or by [CONTACT_577]) prior to enrollment  of the first participant,  and at least  annually  
thereafter,  including  meetings  following  completion  of treatment of the first [ADDRESS_63870]  including  review  of: 
 
• Protocol and ICF changes  
• Protocol violations and  deviations  
• Documentation of informed  consent  
• Enrollment and retention  
• Investigator or key personnel  changes  
• Aggregate analysis of adverse events/serious adverse  events  
• Protection of confidentiality  
 
Followin g each meeting, the board will provide the PI [CONTACT_4490] a report including a recommendation to  continue the  
study  unchanged,  continue  with modifications  of the protocol  and/or  the consent  form to protect  participant  
safety,  or terminate  the study.  Reports  will be submitted  to the IRB on at least  an annual  basis.  
 
[ADDRESS_63871]  the protocol  appropriately.  If the site staff’s  review  of study  documentation  indicates  that additional  
training of study personnel is needed, this will be arranged as per the PI. Study team members will  review each  
other’s  data for completeness,  accuracy,  and fidelity  to the protocol.  
 
20 Statistical Considerations  
 
20.1 Statistical and Analytical Plans (SAP)  
A formal  SAP will be developed  prior to database  lock and unblinding.  
 
20.2 Statistical Hypotheses  
Hypothesis  1a Safety  and tolerability : CBD  will be safe and well tolerated  and will not lead to increased plasma 
THC. No clinically significant cognitive or motoric impairments, CBD -related serious adverse  events,  persisting  
adverse  effects  or treatment  associated  increases  in plasma  THC will be observed.  
 
Hypothesis  1b: Alcohol  use. Relative  to the placebo -treated  group,  CBD-treated  participants  will have  fewer  
drinks  per day during  the 6 weeks  of treatment  with CBD  vs placebo.  
Hypothesis  2: PTSD  symptoms.  Relative  to the placebo -treated  group,  CBD -treated  participants  will lower  
PTSD symptoms during the 6 weeks of treatment with CBD vs  placebo.  
Hypothesis  3a: Mechanism,  traumatic  stress -induced  craving:  Relative  to placebo,  CBD  will be associated  with 
a greater  reduction  between  baseline  and end of treatment  in trauma  induced  alcohol  craving,  negative  emotion,  
and psychophysiological arousal in response to the  task.  
Hypothesis  3b: Mechanism,  AUD  and PTSD  related  measures  and cognition:  Relative  to placebo,  CBD  will 
improve self -report measures of craving, anxiety, mood, self -efficacy and cognitive  performance.  
 
Hypothesis  3c: Mechanism,  anandamide:  Relative  to placebo,  CBD  will be associated  with a greater  increase  
Version :  4.3 #S17 -[ZIP_CODE]  
42  
 in plasma anandamide  levels.  
 
Hypothesis  4: CBD  plasma  levels . Within -group  plasma  CBD  levels  will stabilize  within  one week,  i.e. [ADDRESS_63872] -CBD dosing  levels  obtained  after 1 week  of treatment  will not differ  from those  obtained  after 4 
weeks  of treatment  at each  dose.  
Exploratory  Hypothesis  1: Relationship  between  effects  on PTSD  symptoms  and alcohol  use. The onset  of 
reduction in PTSD symptoms will precede the onset of reduction in alcohol  use. 
 
20.[ADDRESS_63873]  sizes  are remarkably  high.  We will carry  out a full Mixed  Model  Repeated  
Measures  (MMRM)  statistical  analysis  in case  CBD  does  perform  so well. However,  the main  focus  of the 
statistical  analysis  of the results  of the trial will be to characterize  the effect  sizes  and response  rates  across  
the various measurement domains and the profiles of individuals who are treatment successes. The intent  to 
treat (ITT) population will contain all randomized patients w ho receive at least one dose of double -blind  study 
medication and from whom at least one post -baseline (B1) efficacy measurement is obtained while on  study 
medication.  The efficacy  analysis  will be based  on the ITT population.  Two-sided  hypothesis  testing  will be 
utilized.  Tests  with p-values  less than or equal  to 0.[ADDRESS_63874] -wise. All confidence intervals will be two -sided with 95% confidence. Mean  treatment  
effect, standard errors, and 95% confidence intervals will be derived from fully adjusted models on  outcomes  
averaged  across  the treatment  period.  Cohen’s  d and p-values  will be calculated  from fully adjusted  models 
with appropriately transformed outcome variables. For dichotomous drinkin g outcomes, prevalence rates  will 
be calculated.  Odds  ratios  (ORs)  and p-values  will be derived  from logistic  regression  models  including  
treatment  group.  
 
20.3.2  Analysis of the Primary  Endpoint(s)  
For Hypothesis  1a, Safety  and tolerability , the frequency  of adverse  events  will be analyzed  for the entire  
sample at all time points, tabulated for each treatment group, and compared using chi -squared tests.  The 
safety  analysis  will be largely  descriptive  of outcomes  for the entire  study  population.  The incidence  of AEs will 
be summarized  by [CONTACT_2943],  preferred  term,  the likelihood  of its relationship  to the treatment,  and 
severity  for each  treatment  group.  Clinical  laboratory  data will be summarized  by [CONTACT_58696]. Frequency and  
percentage  of patients  whose  values  fall outside  of reference  ranges  will be presented  for each  measurement.  
 
For Hypothesis  1b, Alcohol  Use. The Primary  outcome  measure , number  of drinks  per day, will be analyzed  with 
an MMRM  to assess  differences  in change  from baseline.  The primary  contrast  is change  from baseline  (B1) at 
week  6 (T8).  The model  at each  time point  will include  terms  for treatment,  time and treatment  by [CONTACT_58697] a covariate.  Parameter  estimation  will be based on REML 
and to begin an unstructured covariate matrix will be used.  If the model fails to converge, the  form of the 
covariance matrix will be chosen based on Akaike’s Information Criteria, and Schwa rz’ Bayesian  Criterion. 
Model -based LS means will be obtained for change from baseline to each time point for  each  treatment  group.  
At each  time point,  contrasts  between  CBD  and placebo  will be obtained.  Secondary  alcohol  use measures  will 
be tested  with MMRM  sequentially  in a closed  testing  union  intersection  paradigm  in the order  listed  in section  
C.8.3.  Validity  of the p-value  will extend  until the first test fails to have  a p-value  smaller than  a two-sided  alpha  
of 0.05.  The analyses  will continue  for all measures  but the resulting  p-value  will be nominal.  
 
For Hypothesis  2, PTSD  symptoms,  the primary  outcome  measure,  total score  of the PCL-5, will be analyzed  
in the same  way as the primary  outcome  for alcohol  use. The primary  contrast  is change  from baseline  (B1) at 
week 6  (T8).  
 
20.3.3  Analysis of the Secondary  Endpoint(s)  
For hypothesis 3a: Mechanism, traumatic stress -induced craving: The primary outcome measure will  be alcohol  
craving . Alcohol  craving  outcomes  within  a session  will be examined  in terms  of a created  measure  of a 
difference of difference scores: first, the difference score of the alcohol craving response to trauma and  to 
neutral  challenges  calculated  for the Pre and for the Post session  time points,  and second,  the difference  of the 
Version :  4.3 #S17 -[ADDRESS_63875] and Pre. This difference  measure  of alcohol  craving  will be calculated  at Baseline,  and at 
week 6 of the clinical trial (T8). The outcome analysis will be conducted with an MMRM model  that includes  
fixed  effects  for treatment  C, (CBD  vs. placebo)  and clinical  trial time T, a random  effect  for subjects, and  a 
treatment  by [CONTACT_58698]  (C*T).  The model  will provide  least -square  mean  estimates  of 
difference  scores  at each  session  for each  treatment.  Between  treatment  outcome  contrasts  will be performed  
at Baseline,  as a measure  of the equivalence  of the groups,  and at T6 and for the difference  between  T6 and 
Baseline.  For parameter  estimation,  the form of the covariance  matrix  will follow  the procedures  described  for 
the analysis of Aim 1. Secondary outcome measures will be Negative Emotion, and Psychophysiological  
arousal . These  outcomes  will be analyzed  in a similar  manner  to the primary  outcome,  alcohol  craving. 
 
For Hypothesis 3b: Mechanism, AUD and PTSD related measures and cognition (craving,  self-efficacy,  anxiety,  
cognitive  measures)  will be analyzed  in the same  way as the primary  outcome  for alcohol  use. The primary 
contrast is change from baseline (B1) at week 6  (T8).  
 
For Hypothesis  3c: Mechanism,  anandamide , within - and between -group  comparisons  of plasma  anandamide  
levels  will be assessed  following  45 minutes  (T1),  1 day (T2),  1 week  (T3),  2 weeks (T4), 4 weeks  (T6),  6 weeks  
(T8) of treatment  with CBD  vs. placebo, and one week (T9) after the completion of treatment.  Effects  of dose  
will be assessed  and the interaction  between  group  and time- point will be  evaluated.  
 
For Hypothesis  4, plasma  CBD  and THC levels  will be analyzed  in the same  manner  as anandamide  in 
Hypothesis  3c. 
 
20.3.[ADDRESS_63876]  deviations  of plasma  CBD  and THC levels  within  the CBD treatment group  will be 
presented  following  45 minutes  (T1),  1 day (T2),  1 week  (T3), 2 weeks (T4), 4 weeks  (T6),6 weeks  (T8) of 
treatment  with CBD  vs. placebo, and one week (T9) after the completion of treatment to determine whether 
target plasma levels of CBD have been achieved, and whether  metabolic transformation of CBD to THC has  
occurred.  
The number  of participan ts within  each  treatment  group  that were  able to pass  a battery  of psychomotor  field 
sobriety  tasks  (walk -and-turn task,  one-leg stand,  Romberg’s  test, finger -finger  test, and counting  backwards  
[85]) within  2 hours  of the initial  administration  of CBD  vs. placebo  (T1) will be analyzed  as summary  statistics 
during  treatment.  
AEs and SAEs, when present, will be collected on an AE Case Report Form at study visits . The form  will 
include  an assessment  of clinical  significance  and study  relatedness.  Serious  Adverse  Events  (SAEs)  will be 
documented  on an additional  SAE form.  These  CRFs  will be based  on those  used  in recent  NIDA  Clinical  Trials  
Network  trials.  To further  assess  abuse  potential,  visual  analog  scales  will be used  to assess  abuse  potential. 
Scales will include desire to use the study medication again, desire to use the study  medication again  for 
pleasurable  intoxication  (“to get high”),  and craving  for the study  medication.  
The study  may be stopped  if there  are untoward  and concerning  levels  of Adverse  Event  (AE) or Serious  
Adverse  Event  (SAE)  outcomes  attributable  to CBD  or study  participation.  If the DSMB  finds  it is likely  that CBD 
is contributing to negative outcomes, they will consider solutions including protocol changes  or potentially 
stoppi[INVESTIGATOR_58615].  
 
The frequency  of adverse  events  will be analyzed  for the entire  sample  tabulated  for each  treatment  group  and 
compared  using  chi-squared  tests.  The safety  analysis  will be largely  descriptive  of outcomes  for the entire  
study  population.  The incidence  of AEs will be summarized  by [CONTACT_2943],  preferred  term,  the likelihood  
of its relationship  to the treatment,  and severity  for each  treatment  group.  Clinical  laboratory  data will be 
summarized  by [CONTACT_58696]. Frequency  and percentage  of patients  whose  values  fall outside  of reference  ranges 
will be presented for each  measurement.  
 
20.3.5  Adherence and Retention  Analyses  
Adherence  to the protocol  will be assessed  with a smartphone -assisted  medication  adherence  platform  [94] in 
which  the subject  takes  a video  of drug administration  at each  dose,  and transmits  this to study  personnel.  
 
This program  has been  used  successfully  in previous  studies,  and includes  security  provisions  that ensure  
protection  of confidentiality  and privacy. If the participant is unable to use the smartphone -assisted platform 
then medication adherence will be ensured using pi[INVESTIGATOR_58616] :  4.3 #S17 -[ZIP_CODE]  
44  
 at each visit.  Plasma  concentrations  of CBD  will also be collected  at all in-person visits (T1 -T4, T6, and T8) to 
verify treatment  adherence.  
 
Number  of participants  that complete  the treatment  phase  of the study  (through  T8), complete  the follow -up 
phase of the study (through T10), and are lost to follow -up will be collected. Frequency of and reasons  for 
discontinuation  of the intervention  or study  follow -up will also be tallied.  
 
20.3.6  Baseline Descriptive  Statistics  
Treatment groups will be compared on several baseline characteristics, including sex, age,  race/ethnicity,  
education  level,  baseline  measures  of alcohol  consumption  (% drinking  days  and % heavy  drinking  days),  
alcohol craving (PACS), anxiety (BAI), mood (BDI -II), CAPS total, and self -efficacy (AASE).  Categorical  data 
will be tallied, and means and standard deviations of continuous scores will be  calculated.  
 
20.3.7  Planned Interim  Analysis  
 
[IP_ADDRESS]   Safety  Review  
The DSMB  will meet  (in person  or by [CONTACT_577])  at least annually, including prior to enrollment of the first 
participant, following  completion  of treatment  of the first [ADDRESS_63877] including review of the aggregate analysis of  adverse  events/serious adverse  events.  
Following  each  meeting,  the board  will provide  the PI [CONTACT_4490] a report  including  a recommendation  to continue  the 
study  unchanged,  continue  with modifications  of the protocol  and/or  the consent  form to protect  participant  
safety, or terminate the study. The study may be stopped if there are untoward and concerning levels of AE  or 
SAE outcomes attributable to CBD or st udy participation. If the DSMB finds it is likely that CBD is  contributing 
to negative  outcomes,  they will consider  solutions  including  protocol  changes  or potentially  stoppi[INVESTIGATOR_58617].  
 
20.3.8  Multiple  Comparison/Multiplicity  
Because  our primary  outcomes  are safety  data,  in which  we hypothesize  a null difference  between  treatment  
groups,  we will not employ  a correction  for Type  I error/alpha  inflation.  
 
20.3.9  Tabulation of Individual Response Data  
Aside  from AEs/SAEs,  individual  response  data will not be presented.  
 
20.3.10  Exploratory  Analyses  
 
For Exploratory  Hypothesis  1, relationship  between  PTSD /subthreshold PTSD  and AUD  symptom  change  
 
Symptom  onset  is defined  to be the first week  in which  the patient  has 50% reduction  in the number  of drinks  
per day for the primary  alcohol  outcome  and a 30% reduction  in the Total  Score  of the PCL-[ADDRESS_63878]  two weeks.  Onset  of a positive  clinical  outcome  will be described  by a "cure  model."  The form of a 
cure model is H(t) = 1 - p + pS(t); where H(t) is the probability of onset at a time greater than t, p  represents  
the probability  of success  and S(t) is the distribution  of time to success,  conditional  on success  occurring.  The 
parameters  will be estimated  based  both on Kaplan  Meier  methods  and parametrically.  The equality  of the 
values of p for the two treatment arms will be tested using a nonparametric likelihood ratio test. For  the 
parametric  test, a logistic  will be used  to model  p and a Weibull  survival  distribution  will be used  to model  time 
to failure, S(t). Both allow the use of covariates. The comparison will be based on a likelihood ratio test  and  
the median time to onset of  S(t). 
 
20.4 Sample Size  
We will phone screen  approximately  600 participants,  and enroll  approximately  150 participants  to randomize a 
total of 48 participants (through week 6/T8). In this pi[INVESTIGATOR_58618]. A simple 
t test  of mean  differences  requires  an effect  size of .[ADDRESS_63879] valid hypotheses  tests.  
 
20.5 Measures to Minimize Bias  
Version :  4.3 #S17 -[ZIP_CODE]  
45  
  
20.5.1 Enrollment/Randomization/Masking Procedures  
Enrolled  participants  that pass  screening  will be randomized  using  a 5:3 ratio to  receive  either  600mg CBD/day 
(PO) or placebo  respectively for 6 weeks (N=30 participants on CBD and N=18 participants on placebo).  
Treatment  assignment  will be known  only to a designated  unblinded study staff member in charge of 
dispensing study medication under direct PI [INVESTIGATOR_58619], but  the blind  can be broken  if necessary,  e.g., in case  
of a serious  reaction  during  drug administration.  
 
20.5.2 Evaluation of Success of Blinding  
In order  to assess  the integrity  of the blind,  following  the treatment  portion  of the study  (T8), participants  will be 
asked  to guess  1) what  medication  was administered  (CBD  or placebo),  and 2) degree  of confidence  in this 
guess.  
 
20.5.3 Breaking the Study Blind/Participant Code  
The blind  can be broken  for an individual  participant  if necessary,  e.g., in case  of a serious  reaction  during  drug 
administration  or in the event  of a SAE likely  to be related  to the study  medication.  
 
21 Source Documents and Access to Source  Data/Documents  
Source  data is all information,  original  records  of clinical  findings,  observations,  or other  activities  in a clinical 
trial necessary for the reconstruction and evaluation of the trial. Source data are contained in  source 
documents. Examples of these original documents, and data records include: hospi[INVESTIGATOR_1097], clinical  and 
office charts, laboratory notes, memoranda, subjects’ diaries or evalu ation checklists, study  medication 
dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_58620], microfiches, photographic negatives, microfilm or  magnetic media, 
x-rays,  subject files, and records kept at the dispensation site, at the laboratories, and at  medico - technical  
departments  involved  in the clinical  trial. It is acceptable  to use CRFs  as source  documents.  If this is the case, 
it should be stated in this section what data will be collected on CRFs and what data will  be collected from 
other  sources.  
The study case report form (CRF) is the primary data collection instrument for the study. All data  requested on 
the CRF must be recorded. All missing data must be explained. If a space on the CRF is left  blank  because 
the procedure was not done or the question was not asked, write “N/D”. If the item is not  applicable  to the 
individual case, write “N/A”. All entries should be printed legibly in black ink. If any e ntry error has  been made, 
to correct such an error, draw a single straight line through the incorrect entry and enter  the correct data above 
it. All such changes must be initialed and dated. DO NOT ERASE OR WHITE  OUT  ERRORS. For clarification 
of illegible or uncertain entries, print the clarification above the item, then  initial  and date  it. 
Access to study records will be limited to IRB -approved members of the study team. The investigator  will permit 
study -related monitoring, audits, and inspections by [CONTACT_36985]/EC, the sponsor, government  regulatory bodies,  
and University  compliance  and quality  assurance  groups  of all study  related  documents  (e.g. source documents, 
regulatory documents, data collection instruments, study data etc.). The investigator will  ensure  the capability  
for inspections  of applicable  study -related  facilities  (e.g. dispensation  site, diagnostic  laboratory,  etc.).  
Participation  as an investigator  in this study  implies  acceptance  of potential  inspection  by [CONTACT_58699].  
 
22 Quality Assurance and Quality Control  
Data  quality  assurance  (QA)  includes  all those  planned  and systematic  actions  that are established  to ensure  
that the trial is performed and the data are generated, documented (recorded), and reported in  compliance with  
GCP  and the applicable  regulatory  requirements(s)  (ICH E6 1.46).  Data  quality  control  (QC)  includes  the 
operational techniques and activities undertaken within the quality assurance system to verify that  the 
requirements  for quality  of the trial-related  activities  have  been  fulfilled  (ICH E6 1.47).  
 
QC procedures  will be implemented  beginning  with the data entry  system,  and data QC checks  on the database  
will be generated.  Any missing  data or data anomalies  will be communicated  to the site(s)  for 
clarification/resolution.  
 
Following  written  SOPs,  the monitors  will verify  that the clinical  trial is conducted  and data are generated,  
Version :  4.3 #S17 -[ZIP_CODE]  
46  
 documented (recorded), and reported in compliance with the protocol, GCP, and the applicable  regulatory 
requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP)).  The 
investigational  site will provide  direct  access  to all trial related  sites,  source  data/documents,  and reports  for the 
purpose  of monitoring  and auditing  by [CONTACT_456],  and inspection  by [CONTACT_58700].  
 
23 Ethics/Protection of Human  Subjects  
23.[ADDRESS_63880]  
The investigator  will ensure  that this study  is conducted  in full conformity  with Regulations  for the Protection  of 
Human  Subjects  of Research  codified  in 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, and/or  the ICH E6. 
 
23.[ADDRESS_63881]  
The protocol, informed consent form(s), recruitment materials, and all participant -facing materials will be  
submitted to the IRB for review and approval. Study approval must be  obtained  before  any participant  is 
enrolled.  Any amendment  to the protocol  will require  review  and approval  by [CONTACT_52590]. All changes to the consent form will be IRB approved;  a determination  will be made 
by [CONTACT_58701]-consented.  
 
23.3 Informed Consent Process  
 
23.3.1  Consent/Assent and Other Informational Documents Provided to  Participants  
Consent  forms  describing  in detail  the study  agent,  study  procedures,  and risks are given  to the participant  
and written  documentation  of informed  consent  is required  prior to starting  intervention/administering  study 
product.  
 
23.3.[ADDRESS_63882]  in the study,  to 
assess  whether  they are likely  to qualify  for the study.  Interested  patients  who pass  the pre-screening  
(conducted via phone) will be referred for a screening visit.   
 
• Participants will be provided with an informed consent form,  COVID -19 information sheet,  audio and 
video consent form, and health release form at or prior to their screening visit. Understanding of the 
study procedures will be assessed using a consent quiz.  
 
Subjects will be electronically consented via a 21CFR Part 11 -compliant electronic c onsent method.  The U.S. 
Food and Drug Administration (FDA)’s MyStudies mobile application is a Part 11 -compliant electronic consent 
method which allows our study team to review study informed consent forms with the participants remotely and 
obtain the part icipant’s electronic signatures on the study’s informed consent forms via the mobile application. 
The app is available in the US in English on both Apple and Android smartphones. Secure registration allows 
participants to enter a unique enrollment code spe cific to our study to prevent people outside of the study from 
enrolling. The application allows for the storage of signed electronic consent forms on HIPAA and FISMA 
compliant servers; the participant is able to receive secure copi[INVESTIGATOR_58621]. Designated research staff can easily access and download 
all signed consent forms for secure storage on the shared drive by [CONTACT_58702] a portal. The FDA MyStudies 
e-consent applica tion will not be used until a link to the informed consent form has been submitted and 
approved by [CONTACT_58703]’s IRB. We will also utilize REDCap (accompanied with REDCap Cloud, a Part 11 -compliant 
electronic consent method) to obtain the participant’s electronic signatures on the study’s informed consent 
forms remotely.  
Alternatively, remote consent may be obtained via SendSafe email. In this case, a copy of the consent form 
will be sent via SendSafe email. The subject’s signature [CONTACT_58727] o n the document 
provided, or the subject may print and sign a physical copy that is scanned and returned via the SendSafe 
method. Subjects who do not have access to email or scanner may choose to have a hard copy of the consent 
mailed to them and return via  a self -addressed stamped envelope provided by [CONTACT_3476].  
At or prior to their first visit, participants  will be provided  with an informed  consent  form including  all pertinent  
details  of the study including  descriptions  of the following:  the assessme nt interview  and questionnaires;  the 
follow -up interviews;  description  of experimental  treatment;  risks and benefits  of study  procedures;  alternatives  
Version :  4.3 #S17 -[ZIP_CODE]  
47  
 to participation  in the study; confidentiality; emergency treatment and compensation for injury; payment for 
participation;  a statement that patients will be informed of any new findings affecting the risks or benefits of the 
study;  a statement  that participation  is voluntary  and that the patient  may withdraw  at any time;  and information  
about  whom  to contact  [CONTACT_58704].  The consent  form will also include  assurances  
of confidentiality  and a statement  that participation  is entirely  voluntary,  that the decision  to participate  will in no 
way influence  other  aspects  of the patient’s  treatment,  and that the participant  is free to withdraw  participation  
at any time.  Study staff  will explain  the research  study  to the participant  and answer  any questions  that may 
arise. All participants will receive a verbal explanation in terms suited to their comprehension of  the purposes,  
procedures,  and potential  risks of the study  and of their rights  as research  participants.  Participants  will have  
the opportunity  to carefully  review  the written  consent  form and ask questions  of the study team.  
Participants must pass a consent quiz with a score of 90% or higher prior to signing. Participants who score less 
than 90% may take the quiz a second time after the study team has reviewed content and answered all 
questions. P articipants who are unable to score 90% or higher on the quiz after two attempts will be given a 
copy of the consent to take home and may return for a screening visit on a later date. If the participant is unable 
to score 90% or higher on the third attempt , they will be excluded from the study unless otherwise determined 
by [CONTACT_58705]. If a decision is made to retain the subject despi[INVESTIGATOR_58622] a 90% or 
higher on the consent quiz, the rationale will be documented in the subject’s binder via a note to file.   
A copy  of the signed informed  consent  document  will be given  to the participants  for their records.  The rights  
and welfare  of the participants  will be protected  by [CONTACT_58706]. The  participants  may withdraw  consent  
at any time throughout  the course  of the trial. 
 
A copy of the signed informed consent document will be stored in the subject’s research record. The  consent 
process, including the name [CONTACT_21811], will be thoroughly documented in  the subject’s 
research record. Any alteration to the standard consent process (e.g. use of a translator,  consent from  a legally  
authorized  representative,  consent  document  presented  orally,  etc.) and the justification  for such alteration will 
likewise be  documented.  
 
Patients who consent to participate in the study will also be invited to consent to having their remote and/or in-
person screening assessment s (i.e. SCID  and CAPS ) audio -recorded at the initial visit (see Audio Recording 
Consent)  for quality control and fo r voice -markers analysis . If a patient does not sign the Audio Recording 
Consent, then we will not audio -record the patient’s interview.  
 
Re-Contact[CONTACT_58707] , previously scree ned participants will be 
reconsidered for inclusion in the study.  If a previously screened participant is eligible under the updated  inclusion 
and exclusion  criteria, they will be contact[CONTACT_58708]. If interested, the participant will be brought in for re -consent and a Clinical Re -Screen  or a new 
Screening Visit if [ADDRESS_63883] passed since the initial screening . 
 
Re-Consent  
If the consent is revised (e.g.: new procedures, risk information, compensation, data sharing, etc.), participants 
will be re -consented with the most updated version of the consent form at their next visit. New information that 
could substantially affect a  participant’s desire to continue in the study will be communicated via phone, followed 
by [INVESTIGATOR_1312] -consent at the next study visit.  
 
23.[ADDRESS_63884] of 1996 (HIPAA). Those regulations require a  signed 
subject authorization informing the subject of the  following:  
• What protected health information (PHI) will be collected from subject s in this  study  
• Who will have access to that information and  why 
• Who will use or disclose that  information  
• The rights of a research subject to revoke their authorization for use of their  PHI. 
 
In the event  that a subject  revokes  authorization  to collect  or use PHI, the investigator,  by [CONTACT_5151],  retains 
Version :  4.3 #S17 -[ADDRESS_63885] 
vital status (i.e. that the subject is alive) at the end of their scheduled study  period.  
Participant confidentiality is strictly held in trust by [CONTACT_3486], their staff, and  the sponsor(s)  
and their agents.  This confidentiality  is extended  to cover  testing  of biological  samples in addition to the clinical 
information relating to participants. Therefore, the study  protocol,  documentation, data, and all other 
information generated will be held in strict confidence. No  information  concerning  the study  or the data will be 
released  to any unauthorized  third party  without  prior written  approval  of the  sponsor.  
The study monitor, other authorized representatives of the sponsor, representatives of the IR B or 
pharmaceutical company supplying study product may inspect all documents and records required to  be 
maintained  by [CONTACT_093],  including  but not limited  to, medical  records  (office,  clinic,  or hospi[INVESTIGATOR_307])  and 
records  of drug dispensation  for the participants  in this study.  Records  will be housed  in a secured  space  in 1 
Park, A, C -D, and H buildings of Bellevue Hospi[INVESTIGATOR_58623].  The clinical  study  site will permit access to such  records.  
The study  participant’s  contact  [CONTACT_58709].  At the end of the study,  all records  will continue  to be kept in a secure  location  for as long a period  
as dictated by [CONTACT_58710] 24.2.  
Study  participant  research  data,  which  is for purposes  of statistical  analysis  and scientific  reporting,  will be 
transmitted  to and stored  at NYU  Langone  Medical  Center. This will not include  the participant’s  contact  [CONTACT_58711].  Rather,  individual  participants  and their research  data will be identified  by a unique  
study  identification  number.  The study  data entry  and study  management  systems  used  by [CONTACT_58712].  At the end of the 
study,  all study  databases  will be de-identified  and archived  at the NYU  Langone  Medical  Center.  
Confidentiality  of research  material  will be ensured  by [CONTACT_58713].  Material 
will be available only to project staff, and only as needed. All project staff will be thoroughly trained in  issues  
relating to confidentiality. Participants w ill be identified in case report forms (CRFs) by [CONTACT_58714].  Data  will be entered  into TrialMaster ™, a program  provided by [CONTACT_58703]’s Datacore designed  
specifically  for clinical trials to protect  patient  privacy  and confidentiality.  Published  reports  will be based  on 
group  data;  no individual  data will be reported.  
To further  protect  the privacy  of study  participants,  a Certificate  of Confidentiality  will be obtained  from the NIH. 
This certificate  protects  identifiable  research  information  from forced  disclosure.  It allows  the investigator  and 
others who have access to research records to refuse to disclose identifying information on  research 
participation  in any civil, criminal,  administrative,  legislative,  or other  proceeding,  whether  at the federal,  state, 
or local  level.  By [CONTACT_58715],  Certificates  of Confidentiality  help achieve  the research  objectives  and 
promote  participation  in studies  by [CONTACT_4205][INVESTIGATOR_58624].  
If the study participant has previously participated in a research study at NYU, we will ask the participant’s 
permission to link their previously collected data to the data collected in this research study in order to retain 
longitudinal information on the participant.  
 
23.4.2  Research Use of Stored Human Samples, Specimens, or  Data  
• Intended  Use: Samples  and data collected  under  this protocol  may be used  to evaluate  study  eligibility  
and plasma concentrations of CBD and THC. No genetic testing will be  performed.  
• Storage: Access to stored samples will be limited by [CONTACT_58716] a securely locked  area.  Samples  
and data will be stored using  codes  assigned  by [CONTACT_473].  Data  will be kept in password -
protected  computers.  Only investigators  will have  access  to the samples  and data.  
• Tracking: Data will be tracked using paper and electronic  logs.  
o Disposition at the completion of the study: All stored samples will be sent to GRM  Document  
Management. Study participants who request destruction of samples will be notified  of 
compliance with such request and all supporting details will be maintained for  tracking . 
 
23.5 Future Use of Stored  Data  
Data  collected  for this study  will be analyzed  and in locked  cabinets  in NYU  space  at One Park and within  the 
A, C-D, and H buildings  of Bellevue  Hospi[INVESTIGATOR_58578].  After  the study  is completed,  the de-identified,  archived  
Version :  4.3 #S17 -[ADDRESS_63886]  Keepi[INVESTIGATOR_007]  
24.1 Data Collection and Management  Responsibilities  
Data  collection,  interpretation,  analysis,  review,  and reporting  is the responsibility  of the clinical  trial staff at the 
site under the supervision of the site PI. The investigator is responsible for ensuring the  accuracy,  
completeness, legibility, and timeliness of the data  reported.  
 
All source  documents  will be completed  in a neat,  legible  manner  to ensure  accurate  interpretation  of data.  
Black or blue ink will be used to ensure clarity of reproduced copi[INVESTIGATOR_014]. When making changes or corrections, 
cross  out the original  entry  with a single  line, and initial  and date the change.  We will not erase, overwrite or use 
correction fluid or tape on the original.  
 
Copi[INVESTIGATOR_58625] (eCRF) will be provided for use as source documents and maintained  for recording 
data for each participant enrolled in  the study. Data reported in the eCRF derived from  source documents  will 
be consistent  with the source  documents  or the discrepancies  will be explained  and captured in  a progress  note 
and maintained  in the participant’s  official  electronic  study  record.  
 
Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and  clinical 
laboratory data will be entered into TrialMaster ™ Electronic Data Capture (EDC), a [ADDRESS_63887]  protection  and internal  quality  checks, such  as 
automatic  range  checks,  to identify  data that appear  inconsistent,  incomplete,  or inaccurate.  Clinical  data will 
be entered directly from the source  documents.  
 
24.2 Study Records  Retention  
Study documents will be retained for the longer of 3 years after close -out, 5 years after  final 
reporting/publication,  or [ADDRESS_63888] approval  of a marketing  application  is approved  for the drug for 
the indication  for which  it is being  investigated  or 2 years  after the investigation  is discontinued  and FDA is 
notified  if no application  is to be filed or if the application  has not been  approved  for such  indication.  No records  
will be destroyed  without  the written  consent  of the sponsor,  if applicable.  It is the responsibility  of the sponsor  
to inform  the investigator  when  these  documents  no longer  need  to be retained.  
 
24.3 Protocol Deviations  
A protocol  deviation  is any noncompliance  with the clinical  trial protocol,  GCP,  or Manual  of Procedures  (MOP)  
requirements.  The noncompliance  may be either  on the part of the investigator,  or the study  site staff.  As a 
result  of deviations,  corrective  actions  are to be developed  by [CONTACT_58717].  
 
These practices are consistent with ICH  E6: 
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and  4.5.3  
• 5.1 Quality Assurance and Quality Control, section  5.1.1  
• 5.20 Noncompliance, sections 5.20.1, and  5.20.2.  
 
It is the responsibility  of the site PI/study  staff to use continuous  vigilance  to identify  and report  deviations  
within  [ADDRESS_63889] be reported to the local IRB per their guidelines. The site PI/study staff  is  responsible  
Version :  4.3 #S17 -[ZIP_CODE]  
50  
 for knowing  and adhering  to their IRB requirements.  Further  details  about  the handling  of protocol  deviations 
will be included in the  MOP.  
 
24.4 Publication and Data Sharing  Policy  
This study  will comply  with the NIH Public  Access  Policy,  which  ensures  that the public  has access  to the 
published results of NIH funded research. It requires scientists to submit final peer -reviewed  journal  manuscripts  
that arise  from NIH funds  to the digital  archive  PubMed  Central  upon  acceptance  for publication.  
 
The International Committee of Medical Jour nal Editors (ICMJE) member journals have adopted a  clinical trials 
registration policy as a condition for publication. The ICMJE defines a clinical trial as any  research project  that 
prospectively  assigns  human  subjects  to intervention  or concurrent  comparison  or control  groups  to study the 
cause -and-effect relationship between a medical intervention and a health outcome.  Medical interventions  
include  drugs,  surgical  procedures,  devices,  behavioral  treatments,  process -of-care changes, and  the like. 
Health outcomes  include  any biomedical  or health -related  measures  obtained  in patients  or participants, 
including pharmacokinetic measures and adverse events. The ICMJE policy, and the  Section   [ADDRESS_63890] of 2007, requires that all clinical trials  be  registered  in a public  trials  
registry  such  as ClinicalTrials.gov,  which  is sponsored  by [CONTACT_58718].  Other  biomedical  
journals  are considering  adopting  similar  policies.  For interventional  clinical  trials  performed under NIH IC grants 
and cooperative agreements, it is the grantee’s responsibility to register  the trial in an acceptable registry, so 
the research results may be considered for publication in ICMJE  member journals.  The ICMJE  does  not review  
specific  studies  to determine  whether  registration  is necessary;  instead,  the committee recommends that 
researchers who have questions about the need to register err on the side  of registration  or consult  the editorial  
office  of the journal  in which  they wish to publish.  
 
FDAAA  mandates  that a "responsible  party"  (i.e., the sponsor  or designated  principal  investigator)  register 
and report results of certain "applicable clinical  trials":  
 
• Trials  of Drugs  and Biologics:  Controlled,  clinical  investigations,  other  than Phase  I investigations  of a 
product subject to FDA  regulation;  
• Trials  of Devices:  Controlled  trials  with health  outcomes  of a product  subject  to FDA regulation  (other 
than small feasibility studies ) and pediatric postmarket surveillance  studies.  
• NIH grantees must take specific steps to ensure compliance with NIH implementation of  FDAAA.  
 
25 Study Finances  
25.1 Funding Source  
This study  is financed  through  a grant  from the US National  Institutes  of Health  (NIH)/National  Institute  on 
Alcohol Abuse and Alcoholism  (NIAAA).  
Version :  4.3 #S17 -[ZIP_CODE]  
51  
  
25.2 Costs to the  Participant  
Participants  will not incur  any costs  as a result  of participating  in the study.  
 
25.3 Participant Reimbursements or Payments  
Participants will receive monetary compensation for research assessments as follows:  
 
• Option 1 Screen (S1)= $70  
• Option 2 Screen Session 1 = $50  
• Option 2 Screen Session 2 = $20  
• Baseline (B1)= $70  
• 1-day assessment (T2)= $40  
• 1-week assessment (T3)= $ 60 
• 2-week assessment (T4)= $60  
• 4-week assessment(T6) = $70  
• 6-week assessment (T8)= $70  
• 7-week assessment (T9)= $40  
 
Participants completing all the assessments would therefore receive a total of $ 480. Participants will also be 
provided with a gift card or $12 cash compensation for the purchase of a meal for visits that are 5 hours or longer. 
If requested, compensation will also be provided for travel and transportation for study -related visits.  Participants 
may receive partial compensation for portions o f study visits completed as applicable. Participants may also 
receive a $15 compensation for time/effort spent as a “standby” for a potential screening visit; participants will only 
receive the one -time $15 compensation once the clinical screen visit is co mpleted as part of the study.  
 
In the case of a clinical re -screen or partially completed visits, participants will be compensated $25 -$[ADDRESS_63891]  with this study  (patent  ownership,  royalties,  or financial  gain 
greater  than the minimum  allowable  by [CONTACT_1385],  etc.) must  have  the conflict  reviewed  by [CONTACT_58719] (CIMU)  with a Committee -sanctioned  conflict  management 
plan that has been reviewed and approved by [CONTACT_28833].  All 
NYULMC  investigators  will follow  the applicable  conflict  of interest  policies.
Version :  4.3 #S17 -[ZIP_CODE]  
52  
  
27 References  
 
1. Grant, B.F., et al., Epi[INVESTIGATOR_47970] -5 Alcohol Use Disorder: Results From the  National  
Epi[INVESTIGATOR_58626]. JAMA  Psychiatry,  2015.  72(8): p. 757- 66. 
2. Sacks,  J.J., et al., 2010  National  and State  Costs  of Excessive  Alcohol  Consumption.  Am J Prev Med, 
2015. 49(5): p.  e73-9. 
3. Berglund,  M., A better  widget?  Three  lessons  for improving  addiction  treatment  from a meta -analytical 
study. Addiction, 2005. 100(6): p.  742-50. 
4. Rosner,  S., et al., Opi[INVESTIGATOR_58627].  Cochrane  Database  Syst Rev, 2010(12): 
p. CD001867.  
5. Rosner,  S., et al., Acamprosate  for alcohol  dependence.  Cochrane  Database  Syst Rev, 2010(9):  p. 
CD004332.  
6. Litten,  R.Z.,  et al., Heterogeneity  of alcohol  use disorder:  understanding  mechanisms  to advance  
personalized treatment. Alcohol Clin Exp Res, 2015. 39(4): p.  579-84. 
7. Litten,  R.Z.,  et al., Medications  development  to treat alcohol  dependence:  a vision  for the next decade. 
Addict Biol, 2012. 17(3): p.  513-27. 
8. Litten,  R.Z.,  et al., Research  opportunities  for medications  to treat alcohol  dependence:  addressing  
stakeholders' needs. Alcohol Clin Exp Res, 2014. 38(1): p.  27-32. 
9. Pi[INVESTIGATOR_58628], R.H., et al., Prevalence and Axis I comorbidity of full and partial posttraumatic  stress disorder  
in the United  States:  results  from Wave  [ADDRESS_63892], 2011. 25(3): p.  456-65. 
10. McCarthy,  E. and I. Petrakis,  Epi[INVESTIGATOR_58629]-traumatic stress disorder. CNS Drugs, 2010. 24(12): p.  997-1007.  
11. Baker,  D.G.,  et al., Trauma  exposure,  branch  of service,  and physical  injury  in relation  to mental health  
among  U.S. veterans  returning  from Iraq and Afghanistan.  Mil Med,  2009.  174(8): p. 773-8. 
12. Jacobsen, L.K., S.M. Southwick, and T.R. Kosten, Substance use disorders in patients  with 
posttraumatic  stress  disorder:  a review  of the literature.  Am J Psychiatry,  2001.  158(8): p. 1184 -90. 
13. Kessler,  R.C.,  et al., Lifetime  co-occurrence  of DSM -III-R alcohol  abuse  and dependence  with other  
psychiatric  disorders  in the National  Comorbidity  Survey.  Arch Gen Psychiatry,  1997.  54(4): p. 313- 21. 
14. Kulka,  R., et al., Trauma  and the Vietnam  War Generation:  Report  of Findings  From  the National  Vietnam 
Veterans Readjustment Study. , ed. Brunner/Mazel. 1990, New  York.  
15. Bremner, J.D., et al., Chronic PTSD in Vietnam combat veterans: course of illness and  substance abuse. 
Am J Psychiatry, 1996. 153(3): p.  369-75. 
16. Freeman,  T. and T. Kimbrell,  Relationship  of alcohol  craving  to symptoms  of posttraumatic  stress 
disorder in combat veterans. J Nerv Ment Dis, 2004. 192(5): p.  389-90. 
17. Carter,  A.C.,  C. Capone,  and E.E. Short,  Co-occurring  Posttraumatic  Stress  Disorder  and Alcohol  Use 
Disorders in Veteran Populations. J Dual Diagn, 2011. 7(4): p.  285-299. 
18. McCaul ey, J.L., et al., Posttraumatic  Stress  Disorder  and Co-Occurring  Substance  Use Disorders:  
Advances in Assessment and Treatment. Clin Psychol ([LOCATION_001]), 2012.  19(3). 
19. Simpson,  T.L., et al., Symptoms  of posttraumatic  stress  predict  craving  among  alcohol  treatment  
seekers: results of a daily monitoring study. Psychol Addict Behav, 2012. 26(4): p.  724-33. 
20. Blanco,  C., et al., Comorbidity  of posttraumatic  stress  disorder  with alcohol  dependence  among  US 
adults:  results  from National  Epi[INVESTIGATOR_58630].  Drug  Alcohol  
Depend, 2013. 132(3): p.  630-8. 
21. McLean, C.P., Y.J. Su, and E.B. Foa, Mechanisms of symptom reduction in a combined treatment  for 
comorbid  posttraumatic  stress  disorder  and alcohol  dependence.  J Consult  Clin Psychol,  2015.  83(3): p.  
655-61. 
22. Sells,  J.R., et al., Characterization  of comorbid  PTSD  in treatment -seeking  alcohol  dependent  inpatients:  
Severity  and personality  trait differences.  Drug  Alcohol  Depend,  2016.  163: p. 242-6. 
Version :  4.3 #S17 -[ADDRESS_63893]-traumatic  stress  disorder  and alcohol - use 
disorder. Genes Brain Behav,  2016.  
24. Riggs, D.S., et al., Demographic and social adjustment characteristics of patients with  comorbid 
posttraumatic  stress  disorder  and alcohol  dependence:  potential  pi[INVESTIGATOR_58631].  Addict  
Behav, 2003. 28(9): p.  1717 -30. 
25. Kalman, D., et al., Alcohol dependence, other psychiatric disorders, and health -related quality of  life:  a 
replication  study  in a large  random  sample  of enrollees  in the Veterans  Health  Administration.  Am J Drug 
Alcohol Abuse, 2004. 30(2): p.  473-87. 
26. Bohnert,  K.M.,  et al., The association  between  substance  use disorders  and mortality  among  a cohort of 
Veterans with posttraumatic stress disorder: variation by [CONTACT_58720].  Drug  Alcohol 
Depend, 2013. 128(1-2): p.  98-103. 
27. Gilpin,  N.W.,  Corticotropin -releasing  factor  (CRF)  and neuropeptide  Y (NPY):  effects  on inhibitory  
transmission  in central  amygdala,  and anxiety - & alcohol -related  behaviors.  Alcohol,  2012.  46(4): p. 329-
37. 
28. Gilpin,  N.W.  and M. Roberto,  Neuropeptide  modulation  of central  amygdala  neuroplasticity  is a key 
mediator of alcohol dependence. Neurosci Biobehav Rev, 2012. 36(2): p.  873-88. 
29. de Guglielmo,  G., et al., Recruitment  of a Neuronal  Ensemble  in the Central  Nucleus  of the Amygdala  Is 
Required for Alcohol Dependence. J Neurosci, 2016. 36(36): p.  [ADDRESS_63894]  stress -related 
problem  drinking  in young  adults:  possible  differential  markers  of affective  and impulsive  pathways  of 
risk for alcohol use disorder. Mol Psychiatry, 2016. 21(3): p.  348-56. 
31. Saladin, M.E., et al., PTSD symptom severity as a predictor of cue -elicited drug craving in victims  of 
violent crime. Addict Behav, 2003. 28(9): p.  1611 -29. 
32. Garfinkel, S.N., et al., Impaired contextual modulation of memories in PTSD: an fMRI  and 
psychophysiological  study  of extinction  retention  and fear renewal.  J Neurosci,  2014.  34(40): p. [ZIP_CODE] -
43. 
33. Milad,  M.R.,  et al., Neurobiological  basis  of failure  to recall  extinction  memory  in posttraumatic  stress 
disorder. Biol Psychiatry, 2009. 66(12): p.  [ADDRESS_63895] sizes: results from a  meta -analysis.  
Ann N Y Acad Sci, 2006. 1071 : p. 422-4. 
35. Coffey,  S.F.,  et al., Craving  and physiological  reactivity  to trauma  and alcohol  cues  in posttraumatic  
stress disorder and alcohol dependence. Exp Clin Psychopharmacol, 2010. 18(4): p.  340-9. 
36. Coffey,  S.F.,  et al., Trauma -focused  imaginal  exposure  for individuals  with comorbid  posttraumatic  stress 
disorder and alcohol dependence: revealing mechanisms of alcohol craving in a cue  reactivity paradigm. 
Psychol Addict Behav, 2006. 20(4): p.  425-35. 
37. Petrakis,  I.L., et al., Prazosin  for Veterans  with Posttraumatic  Stress  Disorder  and Comorbid  Alcohol  
Dependence: A Clinical Trial. Alcohol Clin Exp Res, 2016. 40(1): p.  178-86. 
38. Kwako, L.E., et al., Methods for inducing alcohol craving in individuals with co -morbid  alcohol  
dependence  and posttraumatic  stress  disorder:  behavioral  and physiological  outcomes.  Addict  Biol, 
2015. 20(4): p.  733-46. 
39. Nosen,  E., et al., Treatment  of co-occurring  PTSD -AUD:  effects  of exposure -based  and non-trauma  
focused  psychotherapy  on alcohol  and trauma  cue-reactivity.  Behav  Res Ther,  2014.  61: p. 35-42. 
40. Hsiao,  Y.T.,  et al., Effect  of cannabidiol  on sleep  disruption  induced  by [CONTACT_58721]-maze  in rats. Neuropharmacology,  2012.  62(1): p. 373-84. 
41. Alves,  F.H.,  et al., Cannabidiol  injected  into the bed nucleus  of the stria terminalis  modulates baroreflex 
activity through 5 -HT1A receptors. Pharmacol Res, 2010. 62(3): p.  228-36. 
42. Gomes,  F.V.,  et al., Cannabidiol  administration  into the bed nucleus  of the stria terminalis  alters  
cardiovascular responses induced by [CONTACT_58722] 5 -HT(1)A receptor.  Eur 
Neuropsychopharmacol, 2013. 23(9): p.  1096 -104. 
43. Bergamaschi,  M.M.,  et al., Cannabidiol  reduces  the anxiety  induced  by [CONTACT_58723] -naive soc ial phobia patients. Neuropsychopharmacology, 2011. 36(6): p.  1219 -26. 
44. Norris, C., et al., Cannabidiol Modulates Fear Memory Formation Through Interactions  with Serotonergic  
Transmission  in the Mesolimbic  System.  Neuropsychopharmacology,  2016.  41(12): p. 2839 -2850.  
45. Soares  Vde, P., et al., Intra-dorsal  periaqueductal  gray administration  of cannabidiol  blocks  panic -like 
response by [CONTACT_17906] 5 -HT1A receptors. Behavioural brain research, 2010. 213(2): p.  225-9. 
Version :  4.3 #S17 -[ZIP_CODE]  
54  
  
 
46. Baiamonte,  B.A.,  et al., Nicotine  dependence  produces  hyperalgesia:  role of corticotropin -releasing 
factor -1 receptors  (CRF1Rs)  in the central  amygdala  (CeA).  Neuropharmacology,  2014.  77: p. 217- 23. 
47. Campos,  A.C.,  et al., The anxiolytic  effect  of cannabidiol  on chronically  stressed  mice  depends  on 
hippocampal neurogenesis: involvement of the endocannabinoid system. Int J Neuropsychopharmacol, 
2013. 16(6): p.  1407 -19. 
48. Blessing,  E.M.,  et al., Cannabidiol  as a Potential  Treatment  for Anxiety  Disorders.  Neurotherapeutics,  
2015. 12(4): p.  825-36. 
49. McPartland, J.M., et al., Are cannabidiol and Delta(9) -tetrahydrocannabivarin negative modulators  of 
the endocannabinoid system? A systematic review. Br J Pharmacol, 2015. 172(3): p. 737-53. 
50. Roberto,  M., et al., The endocannabinoid  system  tonically  regulates  inhibitory  transmission  and 
depresses  the effect  of ethanol  in central  amygdala.  Neuropsychopharmacology,  2010.  35(9): p. 1962 -
72. 
51. Weiss  F., et al., Cannabidiol:  Long -lasting  amelioration  of vulnerability  states  associated  with relapse 
risk as determined  in animal  models  of drug seeking,  anxiety,  and impulsivity  Alcohol  and Alcoholism,  
2014. 49( No.S1): p.  i1–i69. 
52. Fusar -Poli, P., et al., Distinct  effects  of {delta}9 -tetrahydrocannabinol  and cannabidiol  on neural  
activation during emotional processing. Arch Gen Psychiatry, 2009. 66(1): p.  95-105. 
53. Phelps,  E.A.,  et al., Activation  of the left amygdala  to a cognitive  representation  of fear. Nat Neurosci,  
2001. 4(4): p.  437-41. 
54. Campos,  A.C.,  et al., Cannabidiol,  neuroprotection  and neuropsychiatric  disorders.  Pharmacol  Res, 
2016. 112: p. 119-127. 
55. Iffland,  K. and F. Grotenhermen,  An Update  on Safety  and Side Effects  of Cannabidiol:  A Review  of 
Clinical  Data  and Relevant  Animal  Studies.  Cannabis  Cannabinoid  Res, 2017.  2(1): p. 139-154. 
56. Russo, E.B., et al., Agonistic properties of cannabidiol at 5 -HT1a receptors. Neurochem Res,  2005.  
30(8): p.  1037 -43. 
57. Kathmann, M., et al., Cannabidiol is an allos teric modulator at mu - and delta -opi[INVESTIGATOR_58584].  
Naunyn  Schmiedebergs  Arch Pharmacol,  2006.  372(5): p. 354-61. 
58. Bisogno, T., et al., Molecular targets for cannabidiol and its synthetic analogues: effect on  vanilloid VR1  
receptors  and on the cellular  uptake  and enzymatic  hydrolysis  of anandamide.  Br J Pharmacol,  2001. 
134(4): p.  845-52. 
59. Pandolfo,  P., et al., Cannabinoids  inhibit  the synaptic  uptake  of adenosine  and dopamine  in the rat and 
mouse striatum. Eur J Pharmacol, 2011. 655(1-3): p.  38-45. 
60. de Carvalho,  C.R. and R.N. Takahashi,  Cannabidiol  disrupts  the reconsolidation  of contextual  drug- 
associated memories in Wistar rats. Addict Biol,  2016.  
61. Hamelink,  C., et al., Comparison  of cannabidiol,  antioxidants,  and diuretics  in reversing  binge  ethanol -
induced neurotoxicity. J Pharmacol Exp Ther, 2005. 314(2): p.  780-8. 
62. Fagherazzi, E.V., et al., Memory -rescuing effects of cannabidiol in an animal model of  cognitive 
impairment  relevant  to neurodegenerative  disorders.  Psychopharmacology  (Berl),  2012.  219(4): p. 
1133 -40. 
63. Cheng, D., et al., Long -term cannabidiol treatment prevents the development of social  recognition 
memory  deficits  in Alzheimer's  disease  transgenic  mice.  J Alzheimers  Dis, 2014.  42(4): p. [ADDRESS_63896]  preference  learning  in rats. 
Psychopharmacology (Berl), 2004. 175(3): p.  360-6. 
65. Ren,  Y., et al., Cannabidiol,  a nonpsychotropic  component  of cannabis,  inhibits  cue-induced  heroin  
seeking  and normalizes  discrete  mesolimbic  neuronal  disturbances.  J Neurosci,  2009.  29(47): p. [ADDRESS_63897],  Y.L., et al., Early  Phase  in the Development  of Cannabidiol  as a Treatment  for Addiction:  Opi[INVESTIGATOR_58632]. Neurotherapeutics, 2015. 12(4): p.  807-15. 
67. Consroe,  P., et al., Interaction  of cannabidiol  and alcohol  in humans.  Psychopharmacology  (Berl), 1979. 
66(1): p.  45-50. 
68. Morgan, C.J., et al., Cannabidiol reduces cigarette consumption in tobacco smokers:  preliminary  
findings. Addict Behav, 2013. 38(9): p.  2433 -6. 
69. Crippa,  J.A., et al., Cannabidiol  for the treatment  of cannabis  withdrawal  syndrome:  a case  report.  J Clin 
Pharm Ther, 2013. 38(2): p.  162-4. 
Version :  4.3 #S17 -[ZIP_CODE]  
55  
  
 
70. Fasinu,  P.S.,  et al., Current  Status  and Prospects  for Cannabidiol  Preparations  as New Therapeutic  
Agents. Pharmacotherapy, 2016. 36(7): p. 781-96. 
71. Thiele,  E.A.,  et al., Cannabidiol  in patients  with seizures  associated  with Lennox -Gastaut  syndrome 
(GWPCARE4): a randomised, double -blind, placebo -controlled phase 3 trial. Lancet,  2018.  391([ZIP_CODE]): 
p. 1085 -1096.  
72. Devinsky,  O., J.H. Cross,  and S. Wright,  Trial of Cannabidiol  for Drug -Resistant  Seizures  in the Dravet 
Syndrome. N Engl J Med, 2017.  377(7): p.  699-700. 
73. McGuire,  P., et al., Cannabidiol  (CBD)  as an Adjunctive  Therapy  in Schizophrenia:  A Multicenter 
Randomized Controlled Trial. Am J Psychiatry, 2018. 175(3): p.  225-231. 
74. Leweke, F.M., et al., Therapeutic Potential of Cannabinoids in Psychosis. Biol Psychiatry,  2016.  
79(7): p.  604-12. 
75. Babalonis,  S., et al., Oral cannabidiol  does  not produce  a signal  for abuse  liability  in frequent  marijuana 
smokers. Drug Alcohol Depend, 2016. 172: p. 9-13. 
76. Stott,  C.G.,  et al., A phase  I study  to assess  the single  and multiple  dose  pharmacokinetics  of THC/CBD 
oromucosal spray. Eur J Clin Pharmacol, 2013. 69(5): p.  1135 -47. 
77. Merrick,  J., et al., Identification  of Psychoactive  Degradants  of Cannabidiol  in Simulated  Gastric  and 
Physiological Fluid. Cannabis Cannabinoid Res, 2016. 1(1): p.  102-112. 
78. Sobell,  L.C.,  et al., The reliability  of alcohol  abusers'  self-reports  of drinking  and life events  that occurred 
in the distant past. J Stud Alcohol, 1988. 49(3): p.  225-32. 
79. Flannery,  B.A.,  J.R. Volpi[INVESTIGATOR_48536],  and H.M.  Pettinati,  Psychometric  properties  of the Penn  Alcohol  Craving 
Scale. Alcohol Clin Exp Res, 1999. 23(8): p.  1289 -95. 
80. Ling,  W., et al., Buprenorphine  tapering  schedule  and illicit opi[INVESTIGATOR_20856]. Addiction,  2009.  104(2): p. 256-
65. 
81. DiClemente,  C.C.,  et al., The Alcohol  Abstinence  Self-Efficacy  scale.  J Stud Alcohol,  1994.  55(2): p. 141-
8. 
82. Vielva,  I. and I. Iraurgi,  Cognitive  and behavioural  factors  as predictors  of abstinence  following  treatment 
for alcohol dependence. Addiction, 2001. 96(2): p.  297-303. 
83. Hamilton, M., The assessment of anxiety states by [CONTACT_35254]. Br J Med Psychol, 1959. 32(1): p.  50-5. 
84. Seo, D., et al., Disrupted  ventromedial  prefrontal  function,  alcohol  craving,  and subsequent  relapse risk. 
JAMA Psychiatry, 2013. 70(7): p.  727-39. 
85. Burns,  M., An overview  of field sobriety  test research.  Percept  Mot Skills,  2003.  97(3 Pt 2): p. 1187 - 99. 
86. Martin, W.R., et al., Physiologic, subjective, and behavioral effects of  amphetamine,  methamphetamine, 
ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol  Ther,  1971. 12(2): p.  245-58. 
87. Rosenberg,  S.J., J.J. Ryan,  and A. Prifitera,  Rey Auditory -Verbal  Learning  Test performance  of patients 
with and without memory impairment. J Clin Psychol, 1984. 40(3): p.  785-7. 
88. Vandenberg,  S.G. and A.R. Kuse,  Mental  rotations,  a group  test of three -dimensional  spatial 
visualization. Percept Mot Skills, 1978. 47(2): p.  599-604. 
89. Peters,  M., et al., A redrawn  Vandenberg  and Kuse  mental  rotations  test: different  versions  and factors 
that affect performance. Brain Cogn, 1995. 28(1): p.  39-58. 
90. Conway, A.R., et al., Working memory span tasks: A methodological review and user's  guide.  
Psychon Bull Rev, 2005. 12(5): p.  769-86. 
91. Unsworth, N., Examining variation in working memory capacity and retrieval in cued recall.  Memory, 
2009. 17(4): p.  386-96. 
92. Anton, R.F., et al., Combined pharmacotherapi[INVESTIGATOR_58633]:  
the COMBINE  study:  a randomized  controlled  trial. JAMA,  2006.  295(17): p. 2003 -17. 
93. Bogenschutz,  M.P.,  et al., Psilocybin -assisted  treatment  for alcohol  dependence:  a proof -of-concept  
study. J Psychopharmacol, 2015. 29(3): p.  289-99. 
94. Mooney,  L.J., et al., Utilizing  a Two-stage  Design  to Investigate  the Safety  and Potential  Efficacy  of 
Monthly  Naltrexone  Plus Once -daily Bupropi[INVESTIGATOR_58634] a Treatment  for Methamphetamine  Use Disorder.  J 
Addict Med, 2016. 10(4): p.  236-43. 
95. Sullivan,  J.T., et al., Assessment  of alcohol  withdrawal:  the revised  clinical  institute  withdrawal  
assessment for alcohol scale (CIWA -Ar). Br J Addict, 1989. 84(11): p.  [ADDRESS_63898] for Diagnostic and  Statistical  Manual  
of Mental  Disorders -Fifth Edition  (PCL -5) in veterans.  Psychol  Assess,  2016.  28(11): p. 1379 - 1391.  
97. Sinha,  R., Modeling  relapse  situations  in the human  laboratory.  Curr Top Behav  Neurosci,  2013.  13: p. 
379-402. 
98. Posner, K., et al., The Columbia -Suicide Severity Rating Scale: initial validity and internal consistency 
findings from three multisi te studies with adolescents and adults. Am J Psychiatry, 2011. 168(12): p. 
1266 -77 
99. Beck, A.T., et al., An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin 
Psychol, 1988. 56(6): p. 893 -7. 
100. Beck, A. T., Steer, R. A., & Brown, G. K. (1996) Beck depression inventory -II. San Antonio, 78(2), 490 -
498.. 
101. Weathers, F.W., et al., The Clinician -Administered PTSD Scale for DSM -5 (CAPS -5): Development and 
initial psychometric evaluation in military veterans. Psychol Assess, 2018. 30 (3): p. 383 -395. 
Johsnon, B.A., Ait -Daoud N., & Roache, J.D., The COMBINE SAFTEE: a structured instrument for 
collecting adverse events adapted for clinical studies in the alcoholism field.  Journal of studies on 
alcohol, 2005. 14: p. 157 -67. 
102. Franklin, C. L., Raines, A. M., Chambliss, J. L., Walton, J. L., & Maieritsch, K. P. (2018). Examining 
various subthreshold definitions of PTSD using the Clinician Administered PTSD Scale for DSM -5. 
Journal of affective disorders , 234, 256 -260. 
103. 114. R.H. Pi[INVESTIGATOR_58628], R.B. Goldstein, J.C. Malley, D.C. Johnson, S.M. Southwick. Subsyndromal 
posttraumatic stress disorder is associated with health and psychosical difficulties in veterans of 
operations enduring fr eedom and Iraqi freedom. Depress. Anxiety, 26 (2009), pp. 739 -744 
104. 115. C. Zlotnick, C.L. Franklin, M. Zimmerman. Does “subthreshold” posttraumatic stress disorder have 
any clinical relevance? Compr. Psychiatry, 43 (2002), pp. 413 -419 
105. 116. R.H. Pi[INVESTIGATOR_58628], R. B. Goldstein, S.M. Southwick, B.F. Grant. Prevalence and Axis I comorbidity of 
full and partial posttraumatic stress disorder in the [LOCATION_002]: results from Wave 2 of the National 
Epi[INVESTIGATOR_58635]. J. Anxiety Disor d., 25 (2011), pp. 456 -465 
 
 
 
 
 
 
 
 